Adhera Therapeutics, Inc. - Quarter Report: 2006 September (Form 10-Q)

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

NASTECH PHARMACEUTICAL COMPANY INC.

(Exact name of registrant as specified in its charter)

Delaware		11-2658569
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer Identification No.)
3830 Monte Villa Parkway, Bothell, WA		98021
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (425) 908-3600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ            No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer o            Accelerated filer þ            Non-accelerated filer o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o            No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Date		Class		Shares Outstanding
October 30, 2006		Common stock — $0.006 par value		22,004,264

 

 

NASTECH PHARMACEUTICAL COMPANY INC. AND SUBSIDIARY

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION
ITEM 1 — FINANCIAL STATEMENTS (unaudited)
Condensed Consolidated Balance Sheets as of December 31, 2005 and September 30, 2006			3
Condensed Consolidated Statements of Operations for the three and nine month periods ended September 30, 2005 and September 30, 2006			4
Condensed Consolidated Statement of Stockholders’ Equity and Comprehensive Loss for the nine months ended September 30, 2006			5
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2005 and September 30, 2006			6
Notes to Condensed Consolidated Financial Statements			7
ITEM 2 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS			19
ITEM 3 — QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK			33
ITEM 4 — CONTROLS AND PROCEDURES			33
PART II — OTHER INFORMATION			34
ITEM 1A — RISK FACTORS			34
ITEM 6 — EXHIBITS			34
SIGNATURES			34
EXHIBIT INDEX			35
EXHIBIT 10.19
EXHIBIT 10.27
EXHIBIT 31.1
EXHIBIT 31.2
EXHIBIT 32.1
EXHIBIT 32.2

     Items 1, 2, 3, 4 and 5 of PART II have not been included as they are not applicable.

PART I — FINANCIAL INFORMATION

		December 31,				September 30,
		2005				2006
ASSETS
Current assets:
Cash and cash equivalents		$	26,769			$	21,081
Restricted cash and short-term investments			998				2,155
Short-term investments			32,142				33,174
Accounts receivable			189				2,589
Inventories			2,733				2,758
Prepaid expenses and other current assets			1,545				1,097
Total current assets			64,376				62,854
Property and equipment, net			8,173				14,401
Security deposits and other assets			404				408
Total assets		$	72,953			$	77,663
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	2,944			$	3,433
Accrued payroll and employee benefits			1,740				2,277
Accrued expenses			474				611
Capital lease obligations — current portion			2,431				3,560
Deferred revenue — current portion			1,589				4,074
Total current liabilities			9,178				13,955
Capital lease obligations, net of current portion			3,170				6,093
Deferred revenue, net of current portion			4,250				4,933
Other liabilities			788				1,168
Total liabilities			17,386				26,149
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 100,000 authorized: no shares issued and outstanding:			—				—
Common stock, $0.006 par value; 50,000,000 authorized: 20,750,477 and 21,968,342 shares outstanding at December 31, 2005 and September 30, 2006, respectively			124				132
Additional paid-in capital			176,068				183,250
Deferred compensation			(4,902	)			—
Accumulated deficit			(115,616	)			(131,831	)
Accumulated other comprehensive loss			(107	)			(37	)
Total stockholders’ equity			55,567				51,514
Total liabilities and stockholders’ equity		$	72,953			$	77,663

See accompanying notes to condensed consolidated financial statements.

NASTECH PHARMACEUTICAL COMPANY INC. AND SUBSIDIARY

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2005				2006				2005				2006
Revenues
Product revenue, net			—			$	32				—			$	624
License and research fees		$	1,223				5,130			$	6,155				22,667
Government grants			—				383				—				383
Total revenue			1,223				5,545				6,155				23,674
Operating expenses:
Cost of product revenue			—				13				—				314
Research and development			8,099				10,483				22,559				31,050
Sales and marketing			345				505				963				1,335
General and administrative			2,019				2,942				6,949				9,194
Total operating expenses			10,463				13,943				30,471				41,893
Loss from operations			(9,240	)			(8,398	)			(24,316	)			(18,219	)
Other income (expense):
Interest income			496				751				1,321				2,107
Interest expense			(75	)			(162	)			(265	)			(405	)
Other income and expense, net			5				1				15				11
Loss before change in accounting principle			(8,814	)			(7,808	)			(23,245	)			(16,506	)
Cumulative effect of change in accounting principle			—				—				—				291
Net Loss		$	(8,814	)		$	(7,808	)		$	(23,245	)		$	(16,215	)
Basic and diluted net loss per share:
Loss before change in accounting principle		$	(0.46	)		$	(0.36	)		$	(1.28	)		$	(0.78	)
Cumulative effect of change in accounting principle			—				—				—				0.01
Net loss per common share — basic and diluted		$	(0.46	)		$	(0.36	)		$	(1.28	)		$	(0.77	)
Shares used in computing net loss per share — basic and diluted			19,009				21,408				18,208				21,115

See accompanying notes to condensed consolidated financial statements.

NASTECH PHARMACEUTICAL COMPANY INC. AND SUBSIDIARY

																						Accumulated
										Additional												Other				Total
		Common Stock								Paid-In				Accumulated				Deferred				Comprehensive				Stockholders’
		Shares				Amount				Capital				Deficit				Compensation				Loss				Equity
Balance December 31, 2005			20,750,477			$	124			$	176,068			$	(115,616	)		$	(4,902	)		$	(107	)		$	55,567
Proceeds from the exercise of options			277,899				2				3,054				—				—				—				3,056
Proceeds from the exercise of warrants			694,856				4				5,506				—				—				—				5,510
Compensation related to restricted stock			245,110				2				1,751				—				—				—				1,753
Compensation related to stock options			—				—				2,064				—				—				—				2,064
Cumulative effect of change in accounting principle			—				—				(5,193	)			—				4,902				—				(291	)
Net loss			—				—				—				(16,215	)			—				—				(16,215	)
Change in unrealized loss on available-for-sale securities			—				—				—				—				—				70				70
Comprehensive loss			—				—				—				(16,215	)			—				70				(16,145	)
Balance September 30, 2006			21,968,342			$	132			$	183,250			$	(131,831	)			—			$	(37	)		$	51,514

See accompanying notes to condensed consolidated financial statements.

NASTECH PHARMACEUTICAL COMPANY INC. AND SUBSIDIARY

		Nine Months Ended
		September 30,
		2005				2006
Operating activities:
Net loss		$	(23,245	)		$	(16,215	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash compensation related to stock options			287				2,064
Non-cash compensation related to restricted stock			1,006				1,753
Depreciation and amortization of property and equipment			1,289				1,957
Loss on disposition of property and equipment			124				24
Cumulative effect of change in accounting principle			—				(291	)
Changes in assets and liabilities:
Accounts receivable			(582	)			(2,400	)
Inventories			(977	)			(25	)
Prepaid expenses and other assets			(646	)			444
Accounts payable			1,233				489
Deferred revenue			(1,624	)			3,168
Accrued expenses and other liabilities			(234	)			1,054
Net cash used in operating activities			(23,369	)			(7,978	)
Investing activities:
Property and equipment acquisitions			(4,209	)			(8,209	)
Purchases of investments			(104,280	)			(61,529	)
Sales and maturities of investments			93,699				60,567
Net cash used in investing activities			(14,790	)			(9,171	)
Financing activities:
Change in restricted cash and short-term investments			8,002				(1,157	)
Payments on notes payable			(8,352	)			—
Borrowings under capital lease obligations			2,940				6,286
Payments on capital lease obligations			(1,350	)			(2,234	)
Proceeds from exercise of stock options			5,385				3,056
Proceeds from exercise of warrants			—				5,510
Public offering of common shares			21,648				—
Net cash provided by financing activities			28,273				11,461
Net decrease in cash and cash equivalents			(9,886	)			(5,688	)
Cash and cash equivalents — beginning of period			25,797				26,769
Cash and cash equivalents — end of period		$	15,911			$	21,081
Supplemental disclosures of investing and financing activities:
Cash paid for interest		$	250			$	405
Non-cash investing activity:
Change in unrealized loss on available-for-sale securities		$	54			$	70

See accompanying notes to condensed consolidated financial statements.

NASTECH PHARMACEUTICAL COMPANY INC. AND SUBSIDIARY

Note 1 — Business and Summary of Significant Accounting Policies

Business

     Nastech Pharmaceutical Company Inc. (“Nastech”, or the “Company”) is a pharmaceutical company focusing on the development and commercialization of innovative therapeutic products based on the Company’s proprietary molecular biology-based drug delivery technology for delivering both large and small molecule drugs across mucosal barriers, initially the nasal mucosa, and small interfering RNA (“siRNA”) therapeutics. Using this intranasal technology, the Company creates or utilizes novel formulation components or excipients that can reversibly open “tight junctions” between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. Tight junctions are cell-to-cell connections in various tissues of the body, including the epithelial layer of the intranasal mucosa, the gastrointestinal tract, and the blood brain barrier. They function to provide barrier integrity and to regulate the transport and passage of molecules across these natural boundaries.

     The Company believes its intranasal drug delivery technology could potentially offer advantages over injectable routes for the administration of large molecules such as peptides and proteins. These advantages may include improved safety and clinical efficacy and increased patient compliance due to the elimination of injection site pain and avoidance of injection site irritation. In addition, the Company believes its intranasal drug delivery technology can potentially offer advantages over oral administration by providing for faster absorption into the bloodstream, reduced side effects and improved effectiveness by avoiding problems relating to gastrointestinal and liver metabolism. Although some of the Company’s product candidates use expertise outside this area, this technology is the foundation of its intranasal drug delivery platform and the Company is using it to develop commercial products with collaboration partners or, in select cases, the Company will internally develop, manufacture and commercialize the Company’s products.

     The Company’s RNA interference (“RNAi”) therapeutic programs are targeted at both developing and delivering novel therapeutics using small interfering RNA (“siRNA”) to down-regulate the expression of certain disease causing proteins that are expressed in inflammation, viral respiratory infections and other diseases.

     The Company and its collaboration partners are developing a diverse portfolio of product candidates for multiple therapeutic areas including osteoporosis, obesity, pain, viral infections, inflammation and metabolic diseases. As of September 30, 2006, the Company had 29 patents issued and 281 patent applications filed to protect its proprietary technologies.

     As of September 30, 2006, the Company had an accumulated deficit of approximately $131.8 million and expects to incur additional operating losses in the future as it continues its research and development activities. The Company has funded its operating losses primarily through the sale of common stock in the public markets and private placements and also through revenues provided by its collaborative partners. During 2004, the Company received net proceeds of approximately $65.2 million from public offerings of its common stock pursuant to two shelf registration statements. During 2005, the Company received net proceeds of approximately $21.6 million from a public offering of its common stock pursuant to a shelf registration statement. At September 30, 2006, approximately $10.1 million is available on the Company’s remaining shelf registration statement. On October 19, 2006, the Company filed a shelf registration statement on Form S-3 for $125.0 million of common stock which includes the remaining $10.1 million balance from one of the Company’s previous shelf registration statements. As of the date of this filing, the new $125.0 million shelf has not been declared effective by the SEC. At September 30, 2006, the Company had cash, cash equivalents and short-term investments of approximately $56.4 million, including approximately $2.2 million in restricted cash.

     The Company faces certain risks and uncertainties regarding its ability to generate positive operating cash flow and profits. These risks include, but are not limited to, its ability to obtain additional capital, protect its patents and property rights, overcome uncertainties regarding its technologies, competition and technological change, obtain government approval for products and attract and retain key officers and employees. For a more thorough discussion of risks and uncertainties facing the Company, investors should also read and carefully consider the risk factors beginning on p. 25 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 as may be supplemented or amended by our Quarterly Reports on Form 10-Q.

Basis of Preparation

     The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles for complete financial statements. The accompanying unaudited financial information should be read in conjunction with the audited financial statements, including the notes thereto, as of and for the year ended December 31, 2005, included in the Company’s 2005 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”). The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for each period presented. The results of operations for the interim periods ended September 30, 2006 are not necessarily indicative of the results for the year ending December 31, 2006 or for any future period.

Reclassifications

Certain reclassifications have been made to the 2005 information to conform to the current period presentation including presentation of other income (expense).

Principles of Consolidation

     The consolidated financial statements include the financial statements of Nastech Pharmaceutical Company Inc. and its wholly-owned subsidiary, Atossa HealthCare Inc. (collectively, “the Company”). All inter-company balances and transactions have been eliminated in consolidation.

Use of Estimates

     The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Inventories

     At December 31, 2005 and September 30, 2006, net inventory balances were $2.7 million and $2.8 million and were comprised of raw materials, consisting primarily of bottles, actuators and calcitonin-salmon active pharmaceutical ingredient for the Company’s calcitonin-salmon nasal spray that were acquired by the Company in furtherance of satisfying its supply obligations under its agreement with Par Pharmaceutical. For a discussion of the status of our collaboration with Par Pharmaceutical, See Note 3: Contractual Agreements – Par Pharmaceutical.

Revenue Recognition

     Most of the Company’s revenues are generated from research and licensing arrangements. These research and licensing arrangements may include upfront non-refundable payments, development milestone payments, revenue from product manufacturing, payments for research and development services performed and product sales royalties or revenue. The Company’s revenue recognition policies are based on the requirements of SEC Staff Accounting Bulletin No. 104 “Revenue Recognition,” and, for contracts with multiple deliverables, the Company determines the appropriateness of separate units of accounting and allocates arrangement consideration based on the fair value of the elements under guidance from Emerging Issues Task Force Issue 00-21 (“EITF 00-21”), “Revenue Arrangements with Multiple Deliverables.” Under EITF 00-21, revenue arrangements with multiple deliverables are divided into separate units of accounting such as product development and contract manufacturing. Revenue is allocated to these units based upon relative fair values with revenue recognition criteria considered separately for each unit.

     Nonrefundable upfront technology license fees, for product candidates where the Company is providing continuing services related to product development, are deferred and recognized as revenue over the development period or as the Company provides the services required under the agreement. The ability to estimate total development effort and costs can vary significantly for each product candidate due to the inherent complexities and uncertainties of drug development.

     Milestones, in the form of additional license fees, typically represent nonrefundable payments to be received in conjunction with the achievement of a specific event identified in the contract, such as initiation or completion of specified clinical development activities. The Company believes that a milestone represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on the Company’s part. The Company recognizes such milestones as revenue when they become due and collection is reasonably assured. When a milestone does not represent the culmination of a distinct earnings process, revenue is either recognized when the earnings process is deemed to be complete or in a manner similar to that of an upfront technology license fee.

     The timing and amount of revenue that the Company recognizes from licenses of technology, either from upfront fees or milestones where the Company is providing continuing services related to product development, is dependent upon on the Company’s estimates of filing dates or development costs. As product candidates move through the development process, it is necessary to revise these estimates to consider changes to the product development cycle, such as changes in the clinical development plan, regulatory requirements, or various other factors, many of which may be outside of the Company’s control. The impact on revenue of changes in the Company’s estimates and the timing thereof, is recognized prospectively, over the remaining estimated product development period.

     Royalty revenue is generally recognized at the time of product sale by the licensee.

     Revenue from research and development services performed is generally received for services performed under collaboration agreements, and is recognized as services are performed. Payments received in excess of amounts earned are recorded as deferred revenue.

     Product sales revenue is recognized when the manufactured goods are shipped to the purchaser and title has transferred under our contracts where there is no right of return.

     Under the guidance of EITF Issue 01-14, reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses.

     Government grant revenue is recognized during the period qualifying expenses are incurred for the research that is performed as set forth under the terms of the grant award agreements, and when there is reasonable assurance that the company will comply with the terms of the grant and that the grant will be received.

Income Taxes

     Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company continues to record a valuation allowance for the full amount of deferred tax assets since realization of such tax benefits is not considered to be more likely than not.

Research and Development Costs

     All research and development (“R&D”) costs are charged to operations as incurred. The Company’s R&D expenses consist of costs incurred for internal and external R&D. These costs include direct and research-related overhead expenses. Clinical trial expenses, which are included in R&D expenses, represent obligations resulting from the Company’s contracts with various clinical research organizations in connection with conducting clinical trials for the Company’s product candidates. The Company recognizes expenses for these contracted activities based on a variety of factors, including actual and estimated labor hours, clinical site initiation activities, patient enrollment rates, estimates of external costs and other activity-based factors. The Company believes that this method best approximates the efforts expended on a clinical trial with the expenses recorded. The Company adjusts its rate of clinical expense recognition if actual results differ from its estimates.

     When the Company acquires intellectual properties from others, the purchase price is allocated, as applicable, between In-Process Research and Development (“IPR&D”), other identifiable intangible assets and net tangible assets. The Company’s policy defines IPR&D as the value assigned to those projects for which the related products have not yet reached technological feasibility and have no alternative future use. Determining the portion of the purchase price allocated to IPR&D requires the Company to make significant estimates. The amount of the purchase price allocated to IPR&D is determined by estimating the future cash flows of each project of technology and discounting the net cash flows back to their present values. The discount rate used is determined at the acquisition date, in accordance with accepted valuation methods, and includes consideration of the assessed risk of the project not being developed to a stage of commercial feasibility. Amounts recorded as IPR&D are charged to R&D expense upon acquisition.

Recent Accounting Pronouncements

     In May 2005, the FASB issued Statement of Financial Accounting Standards No. 154, “Accounting Changes and Error Corrections,” (“SFAS 154”). SFAS 154 replaces APB Opinion No. 20, “Accounting Changes,” and SFAS No. 3, “Reporting Accounting Changes in Interim Financial Statements,” and changes the requirements for the accounting for and reporting of a change in accounting principle. The Company adopted SFAS 154 in 2006. The Company’s results of operations and financial condition will only be impacted by SFAS 154 if the Company implements changes in accounting principles that are addressed by the standard or corrects accounting errors in future periods.

     In September 2005, the EITF reached a consensus on Issue No. 04-13, “Accounting for Purchases and Sales of Inventory with the Same Counterparty.” Under EITF 04-13, purchases and sales of inventory with the same counterparty should be considered a single nonmonetary transaction when transacted in contemplation of each other. Nonmonetary exchanges of inventory within the same line of business should be recognized at fair value when finished goods inventory is exchanged for the same or a different type of inventory within the same line of business. The EITF is effective for any transactions completed after March 15, 2006. Adoption of EITF 04-13 did not have a significant impact on the Company’s financial position or results of operations.

     In November 2005, the FASB issued FASB Staff Position No. 123R-3, “Transition Election Related to Accounting for the Tax Effects of Share-Based Payment Awards.” The FSP provides an alternative method of calculating excess tax benefits (the APIC pool) from the method defined in SFAS123R for stock-based payments. A one-time election to adopt the alternate method in this FSP is available to those entities adopting SFAS 123R using either the modified retrospective or modified prospective method. The Company elected not to use this alternate method to calculate its APIC pool at adoption of SFAS 123R.

     In November 2005, the FASB issued FASB Staff Position No. 115-1 and SFAS 124-1, “The Meaning of Other-Than-Temporary Impairment and Its Application to Certain Investments.” The FSP addresses when an investment is considered impaired, whether the impairment is other-than-temporary and the measurement of an impairment loss. The FSP also includes accounting considerations subsequent to the recognition of an other-than-temporary impairment and requires certain disclosures about unrealized losses that have not been recognized as other-than-temporary. The FSP is effective for reporting periods beginning after December 15, 2005 with earlier application permitted. The adoption of this accounting principle did not have a significant impact on the Company’s financial position or results of operations.

     In February 2006, the FASB issued FASB Staff Position SFAS No. 123R-4 “Classification of Options and Similar Instruments Issued as Employee Compensation That Allow for Cash Settlement upon the Occurrence of a Contingent Event.” The FSP amends SFAS 123R for awards with contingent events that are not probable and outside the control of the employee that are settled in cash to classify such awards as an equity award. If the contingent event later becomes probable and the award had been reported as an equity award, the change in classification would be accounted for as a modification. This FSP did not have an impact on the Company’s financial statements or results of operations since the Company does not have such awards.

     In July 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes (“FIN 48”), which prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. Additionally, FIN 48 provides guidance on the recognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The accounting provisions of FIN 48 will be effective for the Company beginning January 1, 2007. The Company is in the process of determining the effect, if any, that the adoption of FIN 48 will have on its consolidated financial position or results of operations.

     In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements,” (“SFAS 157”). SFAS 157 defines fair value, establishes a framework for measuring fair value and requires enhanced disclosures about fair value measurements. SFAS 157 requires companies to disclose the fair value of its financial instruments according to a fair value hierarchy (i.e., levels 1, 2, and 3, as defined). Additionally, companies are required to provide enhanced disclosure regarding instruments in the level 3 category, including a reconciliation of the beginning and ending balances separately for each major category of assets and liabilities. SFAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years. The Company is currently evaluating the impact, if any, adoption may have on its consolidated financial condition or results of operations.

     In September 2006, the FASB released SFAS No. 158, “Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans: an amendment of FASB Statements No. 87, 88, 106, and 132(R),” (“SFAS 158”). SFAS 158 requires an employer to recognize the over funded or under funded status of defined benefit and other postretirement plans as an asset or liability in its statement of financial position and to recognize changes in that funded status in the year in which the changes occur through an adjustment to comprehensive income. This statement also requires an employer to measure the funded status of a plan as of the date of its year-end statement of financial position, with limited exceptions. SFAS 158 is effective as of December 31, 2006. It is expected that SFAS 158 will not have a significant impact on the Company’s consolidated financial condition or results of operations.

     In September 2006, the SEC issued Staff Accounting Bulletin No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements” (“SAB 108”). SAB 108 provides interpretive guidance on how the effects of the carryover or reversal of prior year misstatements should be considered in quantifying a current year misstatement. The SEC staff believes that registrants should quantify errors using both a balance sheet and income statement approach and evaluate whether either approach results in quantifying a misstatement that, when all relevant quantitative and qualitative factors considered, is material. SAB 108 is effective for fiscal years ending on or after November 15, 2006, with early application encouraged. It is expected that SAB 108 will not have a significant impact on the Company’s consolidated financial condition or results of operations.

     In October 2006, the FASB issued FASB Staff Position No. 123R-5, “Amendment of FASB Staff Position FAS 123(R)-1, (“FSP 123(R)-5”). FSP 123(R)-5 amends FSP 123(R)-1 for equity instruments that were originally issued as employee compensation and then modified, with such modification made solely to reflect an equity restructuring that occurs when the holders are no longer employees. In such circumstances, no change in the recognition or the measurement date of those instruments will result if both of the following conditions are met: a) there is no increase in fair value of the award (or the ratio of intrinsic value to the exercise price of the award is preserved, that is, the holder is made whole), or the antidilution provision is not added to the terms of the award in contemplation of an equity restructuring; and b) all holders of the same class of equity instruments (for example, stock options) are treated in the same manner. In September 2006, the Company’s Board of Directors authorized a modification to its stock option plans to provide antidilution adjustments for outstanding stock options in the event of an equity restructuring. These modifications were not added in contemplation of an equity restructuring. In accordance with FSP 123(R)-5, there was no change in the recognition date for the modified options, all holders will be treated in the same manner, and there was no accounting impact and no effect on the Company’s financial condition or results of operations.

Stock-based Compensation

     On January 1, 2006 the Company adopted Statement of Financial Accounting Standards No. 123R, “Share-Based Payment (Revised 2004),” which requires the measurement and recognition of compensation for all stock-based awards made to employees and directors including stock options and employee stock purchases under a stock purchase plan based on estimated fair values. SFAS 123R supersedes previous accounting under Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” for periods beginning in fiscal 2006. In March 2005, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 107 relating to application of SFAS 123R. The Company has applied the provisions of SAB 107 in its adoption of SFAS 123R. In addition to the recognition of expense in the financial statements, under SFAS 123R, any excess tax benefits received upon exercise of options will be presented as a financing activity inflow. The adoption of SFAS 123R will result in recognition of additional non-cash stock-based compensation expense and, accordingly, will increase net loss in amounts which likely will be considered material.

     The Company adopted SFAS 123R using the modified prospective transition method, which requires the application of the accounting standard as of January 1, 2006. In accordance with the modified prospective transition method, the Company’s consolidated financial statements for periods prior to January 1, 2006 have not been restated to reflect this change. Stock-based

compensation recognized during current periods is based on the value of the portion of the stock-based award that will vest during the period, adjusted for expected forfeitures. Stock-based compensation recognized in the Company’s condensed consolidated financial statements for the three and nine month periods ended September 30, 2006 includes compensation cost for stock-based awards granted prior to, but not fully vested as of December 31, 2005 and stock-based awards granted subsequent to December 31, 2005. The compensation cost for awards granted prior to January 1, 2006 is based on the grant date fair value estimated in accordance with the pro forma provisions of SFAS 123 while awards granted after December 31, 2005 follow the provisions of SFAS 123R to determine the grant date fair value and compensation cost. Compensation cost for all stock-based awards is recognized using the straight-line method over the vesting period.

     The adoption of SFAS 123R resulted in a cumulative benefit from accounting change of $291,000 as of January 1, 2006, which reflects the net cumulative impact of estimating future forfeitures in the determination of period expense for restricted stock awards, rather than recording forfeitures when they occur as previously permitted. The impact from the Company’s adoption of SFAS 123R is further described in Note 2.

Net Loss per Common Share

     Basic and diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding during the periods. The effect of employee stock options, unvested restricted stock and warrants at September 30, 2005 and 2006 was not included in the net loss per share calculation for the interim periods then ended as the effect would have been anti-dilutive. Outstanding warrants, employee stock options and unvested restricted stock totaled approximately 4.6 million and 3.8 million shares at September 30, 2005 and 2006, respectively.

Note 2 — Stock-based compensation plans

Determining Fair Value Under SFAS 123R

     Upon adoption of SFAS 123R the Company continued to use the Black-Scholes option pricing model as its method of valuation for stock options. The Company’s determination of the fair value of stock-based awards on the date of grant using an option pricing model is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to the expected life of the award, expected stock price volatility over the term of the award and actual and projected exercise behaviors. Although the fair value of stock options is determined in accordance with SFAS 123R and SAB 107, the Black-Scholes option pricing model requires the input of highly subjective assumptions, and other reasonable assumptions could provide differing results.

     Valuation and Amortization Method. The Company estimates the fair value of stock-based awards on the grant date using the Black-Scholes option valuation model. The Company amortizes the fair value of all awards on a straight-line basis over the requisite service periods, which are generally the vesting periods.

     Expected Life. The expected life of awards granted represents the period of time that they are expected to be outstanding. The Company uses the simplified method prescribed under SAB 107 to determine the expected life based on the average of the vesting period(s) and the contractual life of the option. Stock options granted during the three and nine month periods ended September 30, 2005 have vesting periods of one, three or four years and contractual terms of ten years, resulting in expected terms ranging from five to six-and-one-quarter years. There were no stock options granted during the three month period ended September 30, 2006. Stock options granted during the nine month period ended September 30, 2006 have vesting periods of three years and contractual terms of ten years, resulting in an expected term of six years. Options vesting over multiple years vest proportionately on each annual anniversary date. Outstanding options granted prior to January 1, 2006 have vesting periods of one, three or four years.

     Expected Volatility. The Company estimates the volatility of its common stock at the date of grant based solely on the historical volatility of its common stock. The volatility factor used in the Black-Scholes option valuation model is based on the Company’s historical stock prices over the most recent period commensurate with the estimated expected life of the award.

     Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes option valuation model on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term equal to the expected life of the award.

     Expected Dividend Yield. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model.

     Expected Forfeitures. The Company uses historical data to estimate pre-vesting option forfeitures and records stock-based compensation only for those awards that are expected to vest.

     A summary of the weighted average assumptions and fair values for options granted during the periods presented is as follows:

		Three months ended								Nine months ended
		September 30,								September 30,
		2005				2006				2005				2006
Expected dividend yield			0	%			*				0	%			0	%
Risk free interest rate			4.1	%			*				4.0	%			4.8	%
Expected stock volatility			0.77				*				0.79				0.69
Expected option life		6 years					*			6 years				5.7 years
Weighted average fair value granted during period		$	10.36				*			$	8.65			$	9.05

Stock-based Compensation Under SFAS 123R

     The following table summarizes stock-based compensation expense related to stock-based awards under SFAS 123R for the three and nine month periods ended September 30, 2006:

		Three months ended				Nine months ended
		September 30, 2006				September 30, 2006
		(dollars in thousands)
Stock-based compensation:
Research and development		$	598			$	1,576
Sales and marketing			58				178
General and administrative			589				2,063
Total stock-based compensation		$	1,245			$	3,817

     There were no options granted during the three month period ended September 30, 2006. The weighted average grant-date fair value for options granted during the nine month period ended September 30, 2006 was $9.05. As of September 30, 2006, the Company had approximately $3.9 million of total unrecognized compensation cost related to unvested stock options granted under all equity compensation plans. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. The Company expects to recognize this cost over a weighted average period of approximately 1.5 years.

     The following table presents the impact of the adoption of SFAS 123R on selected line items from the Company’s condensed consolidated financial statements for the three and nine month periods ended September 30, 2006 (in thousands, except per share amounts):

		Three months ended								Nine months ended
		September 30, 2006								September 30, 2006
		As Reported				If Reported				As Reported				If Reported
		Following				Following				Following				Following
		SFAS 123R				APB 25				SFAS 123R				APB 25
Condensed consolidated statement of operations:
Net loss		$	(7,808	)		$	(7,225	)		$	(16,215	)		$	(14,824	)
Net loss per share
Basic and Diluted		$	(0.36	)		$	(0.34	)		$	(0.77	)		$	(0.70	)
Condensed consolidated statement of cash flows:
Net cash provided by (used in) operating activities		$	7,093			$	7,093			$	(7,978	)		$	(7,978	)
Net cash provided by financing activities		$	2,667			$	2,667			$	11,461			$	11,461

Stock Option Activity

     At September 30, 2006, The Company had four stock compensation plans (including its 1990 Stock Option Plan under which no shares are available for future issuance). As of September 30, 2006, under all of the Company’s plans, options to purchase an aggregate of 2.5 million shares were outstanding, and an additional 1.0 million shares were authorized for future grants under the plans. The Company generally issues new shares for option exercises unless treasury shares are available for issuance. The Company has no treasury shares as of September 30, 2006 and has no plans to purchase any in the next year, however, the Company may accept the surrender of vested restricted shares from employees to cover tax requirements at its discretion.

     Options granted, exercised, canceled and expired under all of its stock compensation plans are summarized as follows (options and aggregate intrinsic value in thousands):

										Weighted
						Weighted				Average
						Average				Remaining				Aggregate
						Exercise				Contractual				Intrinsic
		Options				Price				Life				Value
Outstanding December 31, 2005			2,688			$	12.92
Options granted			124				13.98
Options exercised			(278	)			11.81
Options canceled			(7	)			11.05
Options expired			(2	)			12.65
Outstanding at September 30, 2006			2,525			$	13.10			5.9 years				$	6,458
Exercisable at September 30, 2006			1,868			$	12.71			4.9 years				$	5,744

     At September 30, 2006, approximately 1.9 million vested stock options were issued, outstanding and exercisable with a weighted-average exercise price of $12.71 and approximately 0.7 million unvested stock options were issued and outstanding with a weighted average exercise price of $14.20. The $6.5 million aggregate intrinsic value of all stock options outstanding at September 30, 2006 is based on the $15.26 closing market price of the Company’s common stock on that date, and is calculated by aggregating the difference between $15.26 and the exercise price of each of the approximately 2.4 million outstanding vested and unvested stock options which have an exercise price less than $15.26. The total intrinsic value of options exercised during the three and nine month periods ended September 30, 2006 was approximately $0.2 million and $1.5 million, determined as of the date of exercise. The total fair value of options that vested during the three and nine month periods ended September 30, 2006 was approximately $1.9 million and $3.8 million, respectively. The total fair value of options that were forfeited during the three and nine month periods ended September 30, 2006 was approximately $0 and $65,000, respectively.

     The following table summarizes information about stock options outstanding at September 30, 2006:

		Options Outstanding
						Weighted-								Options Exercisable
						Average				Weighted-								Weighted-
						Remaining				Average								Average
						Contractual Life				Exercise								Exercise
Range of Exercise Prices		Outstanding				(Years)				Price				Exercisable				Price
$5.62 - $9.99			351,867				2.4			$	8.20				320,336			$	8.10
$10.00 - $12.43			325,100				4.6				10.95				305,268				10.94
$12.94 - $12.94			800,000				5.6				12.94				800,000				12.94
$13.35 - $16.00			948,433				7.9				14.53				342,201				14.48
$25.00 - $25.00			100,000				5.6				25.00				100,000				25.00
Totals			2,525,400				5.9			$	13.10				1,867,805			$	12.71

Pro Forma Information

     Prior to 2006, stock-based compensation plans were accounted for using the intrinsic value method prescribed in APB 25 and related Interpretations. Stock-based compensation reflected in net loss in the three and nine month periods ended September 30, 2005 related to restricted stock and to one 2002 below-market stock option grant and one 2002 consultant stock option grant, both of which fully vested in 2005. All other stock options granted had exercise prices equal to or greater than the market value of the underlying common stock on the date of grant. Had compensation cost for the plans been determined based on the fair value at the grant dates for

stock options granted in accordance with the method of SFAS 123R, net loss and basic and diluted net loss per share for the three and nine month periods ended September 30, 2005 would have been changed to the pro forma amounts indicated below (in thousands, except per share data):

		Three months ended				Nine months ended
		September 30, 2005				September 30, 2005
		(dollars in thousands)
Net loss as reported		$	(8,814	)		$	(23,245	)
Add: Stock-based employee compensation included in the reported net loss			536				1,293
Deduct: Stock-based employee compensation, determined under fair value based methods			(1,025	)			(3,391	)
Pro forma net loss		$	(9,303	)		$	(25,343	)
Net Loss per share
Basic and diluted — as reported		$	(0.46	)		$	(1.28	)
Basic and diluted — pro forma		$	(0.49	)		$	(1.39	)

     Note 3 — Contractual Agreements

     Procter & Gamble (“P&G”): On January 27, 2006, the Company entered into a Product Development and License Agreement with P&G to develop and commercialize the Company’s PTH(1-34) nasal spray for the treatment of osteoporosis. Clinical and non-clinical studies on PTH(1-34) nasal spray are being completed in preparation for Phase III clinical development. Under terms of the agreement, the Company has granted P&G rights to the worldwide development and commercialization of PTH(1-34) nasal spray in exchange for an upfront fee, potential future milestone payments and royalties on product sales.

     Payments include a $10 million initial payment upon execution of the agreement, a $7 million milestone payment received in June 2006 and the potential for additional contractual payments of up to $15 million during the remainder of 2006. The $10 million initial payment has been recorded as deferred revenue and is being amortized into revenue over the estimated development period. The $7 million milestone payment was recognized in full as revenue in the three month period ended June 30, 2006. In total, milestone payments could reach $577 million over the life of the project depending upon the successful completion of specified development, regulatory and commercialization goals, although there can be no assurance that any such milestones will be achieved. Under the agreement, the Company is eligible to receive double-digit patent-based royalties, with the rate escalating upon the achievement of certain sales levels.

     The Company and P&G will jointly develop PTH(1-34) nasal spray and P&G will reimburse the Company for any development activities performed by the Company under the agreement. P&G will assume responsibility for clinical and non-clinical studies and will direct regulatory approval and worldwide sales, marketing and promotion of PTH(1-34) nasal spray while Nastech will be responsible for the chemistry, manufacturing and controls (CMC) sections of the FDA regulatory submission. In June 2006 the Company announced an agreement with P&G to manufacture and supply PTH(1-34) nasal spray for both clinical and commercial product of this investigational treatment for osteoporosis. Under terms of the supply agreement, the Company will be the exclusive manufacturer of the PTH(1-34) nasal spray and will manufacture the product and supply it to P&G at a transfer price that includes a manufacturing profit if the product is approved.

     Galenea: In February 2006, the Company acquired the RNAi intellectual property (“IP”) estate and other RNAi technologies from Galenea Corporation (“Galenea”). The IP acquired from Galenea includes patent applications licensed from the Massachusetts Institute of Technology that have early priority dates in the antiviral RNAi field focused on viral respiratory infections, including influenza, rhinovirus, and other respiratory diseases. The Company also acquired Galenea’s research and IP relating to pulmonary drug delivery technologies for RNAi. Additionally, the Company assumed Galenea’s awarded and pending grant applications from the National Institute of Allergy and Infectious Diseases (“NIAID”), a division of the National Institutes of Health (“NIH”), and the Department of Defense to support the development of RNAi-based antiviral drugs.

     RNAi-based therapeutics offers a potentially effective treatment for a future influenza pandemic, which the Company believes is an urgent global concern. This program complements the Company’s current TNF-alpha RNAi program targeting inflammation, since a consequence of influenza infection can be life-threatening respiratory and systemic inflammation.

     Consideration for the acquisition consisted of an upfront payment and may include contingent payments based upon the regulatory filing, approval and sale of products. In connection with the transaction, the Company recorded a charge of approximately $4.1

million for acquired research associated with products in development for which, at the acquisition date, technological feasibility had not been established and there was no alternative future use as set forth in Statement of Financial Accounting Standard No. 2, “Accounting for Research and Development Costs.” This charge has been included in research and development expense for the nine months ended September 30, 2006. Additionally, approximately $0.1 million was allocated to purchased fixed assets to be depreciated over estimated remaining useful lives.

     Amylin Pharmaceuticals, Inc.— In June 2006, the Company announced an agreement with Amylin Pharmaceuticals, Inc. (“Amylin”) to develop a nasal spray formulation of exenatide for the treatment of diabetes. Preclinical studies of the formulation have been completed in preparation for initiating studies in human subjects. Amylin filed an Investigational New Drug application (“IND”) with the FDA in July 2006 to allow clinical trials to begin, and began clinical trials in the three month period ended September 30, 2006.

     Under terms of the agreement, the Company will receive milestone payments and royalties on product sales. If the development program is successful and the product continues to move forward, milestone payments could reach up to $89 million in total, based on specific development, regulatory, and commercialization goals. Royalty rates escalate with product success.

     Amylin and the Company will jointly develop the nasal spray formulation utilizing the Company’s proprietary nasal delivery technology, and Amylin will reimburse the Company for any development activities performed by the Company under the agreement. Amylin has overall responsibility for the development program including clinical, non-clinical and regulatory activities, while the Company’s efforts will focus on drug delivery and chemistry, manufacturing and controls (CMC) activities. If a supply agreement is reached between the companies, the Company may supply commercial product to Amylin and their exenatide collaboration partner, Eli Lilly and Company, however, there can be no assurance that such a supply agreement will be executed.

     Par Pharmaceutical — In October 2004, the Company entered into a license and supply agreement with Par Pharmaceutical for the exclusive U.S. distribution and marketing rights to generic calcitonin-salmon nasal spray for the treatment of osteoporosis. Under the terms of the agreement with Par Pharmaceutical, the Company will manufacture and supply finished calcitonin-salmon nasal spray product to Par Pharmaceutical, while Par Pharmaceutical will distribute the product in the US. The financial terms of the agreement include milestone payments, product transfer payments for manufactured product and a profit sharing following commercialization.

     In December 2003, the Company filed with the FDA an Abbreviated New Drug Application (“ANDA”) for a calcitonin-salmon nasal spray for the treatment of osteoporosis, and in February 2004, the FDA accepted the filing of the Company’s ANDA for the product with no request for additional clinical studies. To date, the FDA has conducted Pre-Approval Inspections (“PAI”) of both of the Company’s nasal spray manufacturing facilities and has informed the Company the facilities were approved for supplying calcitonin-salmon nasal spray. On September 2, 2005, a citizen’s petition was filed with the FDA requesting that the FDA not approve the ANDA as filed prior to additional studies for safety and bioequivalence. On October 13, 2005, the Company filed a response requesting that the FDA deny this citizen’s petition on the grounds that no additional information is necessary from a scientific or medical basis and that such additional information is not required under the law. On March 15, 2006, the petitioner submitted an additional request to the FDA in response to the Company’s assertions in its October 13, 2005 submission to the FDA. On May 11, 2006 the Company filed an additional response requesting that the FDA deny the citizen’s petition.

     In addition, Apotex, Inc. (“Apotex”) has filed a generic application for its nasal calcitonin-salmon product with a filing date that has priority over the Company’s ANDA for its calcitonin-salmon nasal spray which prevents the Company from marketing its product until 180 days after Apotex commences marketing its product. In November 2002, Novartis AG (“Novartis”) brought a patent infringement action against Apotex claiming that Apotex’s nasal calcitonin-salmon product infringes on Novartis’ patents, seeking damages and requesting injunctive relief. That action is still pending. The Company is unable to predict what, if any, effect the Novartis action will have on Apotex’s ability or plans to commence marketing its product or when, if at all, Apotex will commence marketing its product.

     On July 10, 2006, the Company received written notification from the FDA stating that the Company’s ANDA for nasal calcitonin-salmon was not approvable at this time. The FDA expressed a concern relating to the potential for immunogenicity that might result from a possible interaction between calcitonin-salmon and chlorobutanol, the preservative in the formulation although no allergic reactions have been observed in any of the clinical trials conducted by the Company and other existing marketed nasal spray products contain chlorobutanol as the preservative. On September 29, 2006, the Company announced that it had submitted a complete response to the FDA’s Office of Generic Drugs regarding the potential for such immunogenicity. The FDA has accepted the Company’s submission for review, indicating that the generic division of the FDA has maintained jurisdiction of the Company’s filing. Furthermore, the FDA has indicated that the Company’s response is classified as a major amendment to the ANDA, and the Company therefore expects that the FDA will take at least six months to complete its review of the Company’s submission. If the Company is not successful at keeping this application as an ANDA then a 505(b)(2) NDA may be pursued or the application may be withdrawn. At this time the Company is not able to determine when, if at all, the Company’s calcitonin product will receive marketing approval from the FDA.

     The Company’s formulation of calcitonin-salmon nasal spray was specifically developed to be similar to Novartis’ currently marketed calcitonin-salmon nasal spray, Miacalcin^®, in order to submit the application as an ANDA. Thus, the Company’s formulation does not utilize the Company’s advanced tight junction drug delivery technology, which is currently being used in development of its proprietary pipeline of peptide and protein therapeutics.

     Questcor Pharmaceuticals, Inc. — In September 2003, the Company completed the sale of certain assets relating to its Nascobal^® brand products, including the Nascobal^® (Cyanocobalamin USP) nasal gel and nasal spray, to Questcor Pharmaceuticals, Inc. (“Questcor”). The Company filed a New Drug Application (“NDA”) of a nasal spray product configuration of Nascobal^® in 2003 and was to continue to prosecute the pending U.S. patents for the Nascobal^® nasal spray product on behalf of Questcor. The Company recognized a gain of approximately $4.2 million on the sale of the assets in 2003. The gain was calculated as $14 million in non-contingent proceeds, less the net book value of the assets of $8.1 million, less costs and fees. At the date of the sale, approximately $1 million of the gain relating to the fair value of work to be completed on the filing of the NDA for the Nascobal^® nasal spray product was deferred and recognized later in 2003 as revenue.

     Under the terms of the Asset Purchase Agreement, between the Company and Questcor, Questcor paid the Company $9 million at closing, $3 million in September 2003 and approximately $2.2 million in December 2003. In connection with the sale, the Company paid in full a $6.9 million promissory note and accrued interest of $110,000 due to the company that Nastech had acquired Nascobal^® from, which such company subsequently released its security interest in Nascobal^® assets. Questcor also agreed to make payments of: (i) $2.0 million contingent upon FDA approval of a New Drug Application for the Nascobal^® nasal spray product; and (ii) $2.0 million contingent upon issuance of a U.S. patent for the Nascobal^® nasal spray product. FDA approval for the Nascobal^® nasal spray product was granted in January 2005, and the $2.0 million payment due upon this milestone was received from Questcor in February 2005.

     Under the terms of a supply agreement between the parties, subject to certain limitations, the Company was obligated to manufacture and supply all of Questcor’s requirements and Questcor was obligated to purchase from the Company all of its requirements for Nascobal^® nasal gel and spray.

     Questcor assignment to QOL Medical, LLC — On October 17, 2005, with the consent of the Company, Questcor assigned all of its rights and obligations under the Questcor Asset Purchase and Supply Agreements dated September 2003 to QOL Medical, LLC (“QOL”). The Company received $2.0 million from Questcor on October 19, 2005 in consideration for its consent to the assignment and in connection with the Company entering into an agreement with QOL which modified certain terms of the Asset Purchase and Supply Agreements. The $2.0 million is being recognized on a straight-line basis over the five-year life of the QOL agreement.

     Alnylam Pharmaceuticals, Inc. — On July 20, 2005, the Company announced that it had acquired an exclusive InterfeRx™ license from Alnylam Pharmaceuticals, Inc. (“Alnylam”) to discover, develop, and commercialize RNAi therapeutics directed against TNF-alpha, a protein associated with inflammatory diseases including rheumatoid arthritis and certain chronic respiratory diseases. Under the agreement, Alnylam received an initial license fee from the Company and is entitled to receive annual and milestone fees and royalties on sales of any products covered by the licensing agreement. The initial license fee was expensed as research and development expenses by the Company in 2005.

     Merck/PYY — In September 2004, the Company entered into an Exclusive Development, Commercialization and License Agreement and a separate Supply Agreement (collectively, the “Agreements”) with Merck, for the global development and commercialization of PYY Nasal Spray, the Company’s product for the treatment of obesity. Under the Agreements, the Company received an initial cash payment of $5 million in 2004. The $5 million initial payment was being amortized over the estimated development period, and was initially recorded as deferred revenue in the accompanying balance sheet. The Agreements entered into with Merck in September 2004 for PYY were terminated on March 1, 2006. Under the agreement, Nastech reacquired its rights in the PYY program. The unamortized $3.7 million balance of the $5 million initial payment was recognized as revenue in the nine-month period ended September 30, 2006.

     The Company has continued PYY product development on its own, and on August 14, 2006, the Company announced the initiation of a dose ranging study designed to evaluate the pharmacokinetic parameters, appetite, food intake and safety of various doses of Nastech’s PYY nasal spray in obese subjects.

     Government Grants — On August 29, 2006, the Company announced that the NIH awarded the Company a Phase 1 Small Business Innovation Research (SBIR) grant of $383,000 to further develop the Company’s siRNA therapeutics to prevent and treat influenza. These funds were received by the Company in September 2006 and recognized as grant revenue during the three month period ended September 30, 2006. On September 26, 2006, the Company announced that the NIH awarded the Company a $1.9 million Research Project (R01) grant to prevent and treat influenza.

Note 4 — Stockholders’ Equity

     Common Stock Offerings — In a 2001 private offering, the Company granted warrants to purchase 68,000 shares of its common stock at any time prior to May 11, 2005, at an exercise price of $7.50 per share of common stock. As of December 31, 2005, all warrants relating to this private placement have been exercised. In connection with such private placement, the Company granted additional warrants to purchase 595,155 shares of its common stock, of which 430,062 warrants were exercisable at any time prior to March 22, 2006 and 165,093 warrants were exercisable at any time prior to May 11, 2006, at an exercise price of $6.34 per share. As of September 30, 2006, all warrants issued in connection with these private placements have been exercised.

     In September 2003, the Company completed the sale of 1,513,069 units, each unit consisting of one share of common stock and one five year warrant convertible into 0.35 common shares, to certain accredited investors in a private placement transaction for an aggregate purchase price of $11 million, prior to the deduction of fees and commissions totaling $1,037,000. The units were sold at $7.27 per unit, which was an 18% discount from the volume weighted average stock price for the 10 days prior to the completion of the private placement transaction. The warrants are exercisable for 529,574 shares of common stock at an exercise price per share of $11.09, subject to adjustment from time to time for stock splits, stock dividends, distributions or similar transactions. The warrants expire in September 2008. At September 30, 2006, 337,001 warrants issued in connection with this private placement had been exercised.

     In June, 2004, the Company completed the sale of 1,136,364 shares of its common stock, and warrants to purchase up to 511,364 shares of common stock at an exercise price of $14.40 per share, pursuant to its $30 million effective shelf registration statement. Subsequent dilution has resulted in a contractual reduction in exercise price to $14.26 and an increase in warrants outstanding to 516,384. The offering resulted in gross proceeds of approximately $12.5 million to the Company prior to the deduction of fees and commissions of $229,000. The warrants vested in December 2004, and are exercisable until June 2009. At September 30, 2006, no warrants issued in connection with this private placement have been exercised.

     In December 2004, the Company completed the public offering of 4,250,000 shares of its common stock at a public offering price of $13.50 per share pursuant to its $80 million effective shelf registration statement. The offering resulted in gross proceeds of approximately $57.4 million to the Company, prior to the deduction of fees and commissions of $4.5 million.

     In August 2005, the Company completed the public offering of 1,725,000 shares of its common stock at a public offering price of $13.50 per share pursuant to its $80 million effective shelf registration statement and a $0.7 million post effective amendment filed on August 25, 2005 pursuant to Rule 462(b) of the Securities Act. The offering resulted in gross proceeds of approximately $23.3 million to the Company, prior to the deduction of fees and commissions of approximately $1.7 million.

     Warrants — Additional information on warrants for the Company’s common stock is as follows:

		Exercise Price of Warrants												Total
		$6.34				$11.09				$14.26				Warrants
Warrants outstanding at December 31, 2005			458,395				433,288				516,384				1,408,067
Exercised during the nine months ended September 30, 2006			(458,395	)			(240,715	)			—				(699,110	)
Warrants outstanding at September 30, 2006			—				192,573				516,384				708,957
Warrants expiring in September 2008			—				192,573				—				192,573
Warrants expiring in June 2009			—				—				516,384				516,384

     Restricted Stock Awards — Pursuant to restricted stock awards granted under the Company’s 2004 Plan, the Company has issued shares of restricted stock to certain employees and members of the board of directors. Non-cash compensation expense is being recognized on a straight-line basis over the applicable vesting periods of one to four years of the restricted shares based on the fair value of such restricted stock on the grant date. Additional information on restricted shares is as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2005				2006				2005				2006
Unvested restricted shares outstanding, beginning of period			148,823				493,228				145,620				444,322
Restricted shares issued			308,169				125,710				389,052				276,656
Restricted shares forfeited			(15,955	)			(2,328	)			(25,515	)			(14,635	)
Restricted shares vested			(14,703	)			(76,096	)			(82,823	)			(165,829	)
Unvested restricted shares outstanding, end of period			426,334				540,514				426,334				540,514
Non-cash restricted stock compensation expense, net of forfeitures		$	492,000			$	547,000			$	1,006,000			$	1,753,000
Average award price during period		$	14.59			$	13.04			$	13.85			$	14.26

     Shelf Registration Statement — At September 30, 2006, the Company had one effective shelf registration statement on Form S-3. A shelf registration statement enables the Company to raise capital from the offering of securities covered by the shelf registration statements, as well as any combination thereof, from time to time and through one or more methods of distribution, subject to market conditions and cash needs. In December 2003, the Company filed a shelf registration statement with the SEC, which was declared effective by the SEC on January 14, 2004, pursuant to which it may issue common stock or warrants, up to an aggregate of $30 million. The balance remaining on this shelf registration at September 30, 2006 is approximately $10.1 million. On October 19, 2006, the Company filed a shelf registration statement on Form S-3 for $125.0 million of common stock which includes the remaining $10.1 million balance from one of the Company’s previous shelf registration statements. As of the date of this filing, the new $125.0 million shelf has not been declared effective by the SEC.

     Stockholders’ Rights Plan — In 2000, the Company enacted a stockholder rights plan designed to protect its stockholders from coercive or unfair takeover tactics. Under the plan, the Company declared a dividend of one preferred stock purchase right for each share of common stock and entered into a Rights Agreement with the Company’s stock transfer agent. Each preferred stock purchase right entitles the holder to purchase from the Company 1/1000 of a share of its Series A Junior Participating Preferred Stock for $50. In the event any acquiring entity or group accumulates or initiates a tender offer to purchase 15% or more of the Company’s common stock, then each holder of the Company’s common stock shall receive a separate certificate evidencing the rights (the “Rights Distribution”). Each holder of preferred stock purchase rights, other than the acquiring entity, will have the right to receive, upon exercise of the preferred stock purchase rights, shares of the Company’s common stock or shares in the acquiring entity having a value equal to two times the exercise price of the preferred stock purchase rights.

ITEM 2 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

     Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by us. These factors include, but are not limited to: (i) our ability to obtain additional funding; (ii) our ability to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) our and/or a partner’s ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (iv) our and/or a partner’s ability to obtain required governmental approvals, including product and patent approvals; and (v) our and/or a partner’s ability to develop and commercialize products that can compete favorably with those of competitors. In addition, significant fluctuations in quarterly results may occur as a result of the timing of milestone payments, the recognition of revenue from milestone payments and other sources not related to product sales to third parties, and the timing of costs and expenses related to our research and development programs. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in our filings with the Securities and Exchange Commission, including those factors discussed under the captions “Forward-Looking Information” and “Risk Factors” in our most recent Annual Report on Form 10-K, as may be supplemented or amended by our Quarterly Reports on Form 10-Q, which we urge investors to consider. We undertake no obligation to publicly release revisions in such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events or circumstances, except as otherwise required by securities and other applicable laws.

     We are a pharmaceutical company focusing on the development and commercialization of innovative therapeutic products based on our proprietary molecular biology-based drug delivery technology for delivering both large and small molecule drugs across mucosal barriers, initially the nasal mucosa, and small interfering RNA (“siRNA”) therapeutics. Using our intranasal technology, we create or utilize novel formulation components or excipients that can reversibly open “tight junctions” between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. Tight junctions are cell-to-cell connections in various tissues of the body, including the epithelial layer of the intranasal mucosa, the gastrointestinal tract, and the blood brain barrier. They function to provide barrier integrity and to regulate the transport and passage of molecules across these natural boundaries.

     We believe our intranasal drug delivery technology could potentially offer advantages over injectable routes for the administration of large molecules such as peptides and proteins. These advantages may include improved safety and clinical efficacy and increased patient compliance due to the elimination of injection site pain and avoidance of injection site irritation. In addition, we believe our intranasal drug delivery technology can potentially offer advantages over oral administration by providing for faster absorption into the bloodstream, reduced side effects and improved effectiveness by avoiding problems relating to gastrointestinal and liver metabolism. Although some of our product candidates use our expertise outside this area, this technology is the foundation of our intranasal drug delivery platform and we are using it to develop commercial products with collaboration partners or, in select cases, we internally develop, manufacture and commercialize our products.

     Our RNAi therapeutic programs are targeted at both developing and delivering novel therapeutics using siRNA to down-regulate the expression of certain disease causing proteins that are expressed in inflammation, viral respiratory infections and other diseases.

     Our goal is to become a leader in both the development and commercialization of innovative, intranasal drug delivery products and technologies and in therapeutic RNAi. Key elements of our strategy include:

	•		Applying Our Tight Junction Technology and Other Drug Delivery Methods to Product Candidates. We will focus our research and development efforts on product candidates, including, peptides, large molecules, small molecules and therapeutic siRNA, where our proprietary technologies utilizing tight junctions may offer clinical advantages such as improved safety and clinical efficacy or increased patient compliance due to elimination of injection site pain and avoidance of injection site irritation. We will also continue to search for applications of our tight junction technology to improve other forms of drug delivery, including oral, pulmonary and intravenous delivery.
	•		Pursuing Collaborations with Pharmaceutical and Biotechnology Companies. We will continue to try to establish strategic collaborations with pharmaceutical and biotechnology companies. Typically, we collaborate with partners to commercialize our product candidates by utilizing their research and development, regulatory compliance, marketing and distribution capabilities. We may also assist our collaboration partners in developing more effective drug delivery methods for their product candidates that have already completed early stage clinical trials, or are even currently marketed. We intend to structure our collaborative arrangements to receive research and development funding and milestone payments during the development phase, revenue from manufacturing upon commercialization and patent-based royalties on future sales of products.
	•		Strategically Developing and Commercializing Product Candidates on Our Own. In select cases where we deem it to be strategically advantageous to us, we plan to internally develop, manufacture and distribute our products.
	•		Utilizing Our Manufacturing Expertise and Capabilities. We have invested substantial time, money and intellectual capital in developing our manufacturing facilities and know-how which we believe would be difficult for our competitors to replicate easily. These capabilities give us competitive advantages including the ability to prepare the chemistry, manufacturing and controls section of the new drug application (the “NDA”) filing with the U.S. Food and Drug Administration (the “FDA”) and maintain a high-level of quality control in manufacturing product candidates for clinical trials and FDA-approved products for commercialization. We believe our manufacturing capabilities will meet our projected capacity needs for the foreseeable future.

     We are engaged in a variety of research, preclinical and clinical development activities to identify and develop viable product candidates in therapeutic areas including osteoporosis, obesity, pain, antivirals, inflammation and metabolic diseases. We and our collaboration partners have been developing a diverse portfolio of clinical-stage product candidates for multiple therapeutic areas utilizing our molecular biology-based drug delivery technology. In addition, we have been expanding our RNAi research and

development efforts, especially in the pre-clinical area, and have been acquiring and developing an RNAi IP estate and expanding our RNAi pipeline in multiple therapeutic areas. As of September 30, 2006, we had 29 patents issued and 281 patent applications filed to protect our proprietary technologies.

     As of September 30, 2006, we had an accumulated deficit of $131.8 million and expect additional operating losses in the future as we continue our research and development activities. Our development efforts and the future revenues from sales of these products are expected to generate contract research revenues, milestone payments, license fees, patent-based royalties and manufactured product sales for us. As discussed elsewhere, in February 2006, we received a $10.0 million license fee from P&G and in June 2006 we received a $7.0 million milestone payment from P&G. We expect to receive additional contractual payments in 2006 from P&G under the February 2006 license agreement.

     Procter & Gamble Partnership

     On January 27, 2006, we entered into a Product Development and License Agreement with P&G to develop and commercialize our PTH(1-34) nasal spray for the treatment of osteoporosis. Clinical and non-clinical studies on PTH(1-34) nasal spray are being completed in preparation for Phase III clinical development. Under terms of the agreement, we have granted P&G rights to the worldwide development and commercialization of PTH(1-34) nasal spray in exchange for an upfront fee, research and development expense reimbursements and the potential for future milestone payments and royalties on product sales.

     Payments include a $10 million license fee received upon execution of the agreement, a $7 million milestone fee received in June 2006 and the potential for additional contractual payments of up to $15 million during the remainder of 2006. The $10 million initial payment received in has been recorded as deferred revenue and is being amortized into revenue over the estimated development period. The $7 million milestone payment was recognized in full as revenue in the three months ended June 30, 2006. In total, milestone payments could reach $577 million over the life of the project depending upon the successful continuation of the development program, completion of specified development, regulatory and commercialization goals, although there can be no assurance that any such milestones will be achieved. Under the agreement, upon commercialization we are eligible to receive double-digit percentage patent-based royalties, with the rate escalating upon the achievement of certain sales levels.

     We will jointly develop PTH(1-34) nasal spray with P&G and will be reimbursed by P&G for development activities we perform under the agreement. P&G will assume responsibility for clinical and non-clinical studies and regulatory approval while we will be responsible for the chemistry, manufacturing and controls sections of regulatory submissions. In June 2006 we announced an agreement with P&G to manufacture and supply PTH(1-34) nasal spray for both clinical and commercial product of this investigational treatment for osteoporosis. Under terms of the supply agreement, Nastech will be the exclusive manufacturer of the PTH(1-34) nasal spray and will manufacture the product and supply it to P&G at a transfer price that includes a manufacturing profit if the product is approved by the FDA. P&G will direct worldwide sales, marketing, and promotion of PTH(1-34) nasal spray.

     PTH(1-34), a part of the naturally occurring human parathyroid hormone that helps regulate calcium and phosphorus metabolism and causes bone growth is the same active ingredient that is being marketed as an injectable product, Forteo^® by Eli Lilly and Company (“Lilly”). We have developed a proprietary intranasal formulation of PTH(1-34) and as of September 30, 2006 have filed ten U.S. patent applications containing an aggregate of 317 claims, and one Patent Cooperation Treaty (“PCT”) Application.

     We launched the clinical program for PTH(1-34) intranasal spray in 2004 and have completed four Phase I clinical trials. In March 2005, we met with the FDA at which time they advised us that, based on their current interpretation of FDA regulations, we may submit a Section 505(b)(2) application for our PTH(1-34) intranasal spray. The 505(b)(2) pathway is a regulatory pathway for certain drugs that are already approved and on the market, but for which a change in dose, a change in indication, or a change in delivery route is being pursued. Through the 505(b)(2) process, the FDA can use their administrative findings of safety and efficacy of another sponsor’s NDA, in this case, Forteo^®, to allow us to conduct a limited pre-clinical and clinical program, which we believe will shorten the timeline for the achievement of full commercialization and reduce the cost for developing the program. Once we submit our 505(b)(2) application, the FDA will review it as it does any other application.

     Amylin Pharmaceuticals, Inc.— In June 2006, we announced an agreement with Amylin Pharmaceuticals, Inc. (“Amylin”) to develop a nasal spray formulation of exenatide for the treatment of diabetes. Preclinical studies of the formulation have been completed in preparation for initiating studies in human subjects. Amylin filed an Investigational New Drug application (“IND”) with the FDA in July 2006 to allow clinical trials to begin, and began clinical trials in the three month period ended September 30, 2006.

     Under terms of the agreement, we will receive milestone payments and royalties on product sales. If the development program is successful and the product continues to move forward, milestone payments could reach up to $89 million in total, based on specific development, regulatory, and commercialization goals. Royalty rates escalate with product success.

     We and Amylin will jointly develop the nasal spray formulation utilizing our proprietary nasal delivery technology, and Amylin will reimburse us for any development activities performed by us under the agreement. Amylin has overall responsibility for the development program including clinical, non-clinical and regulatory activities, while our efforts will focus on drug delivery and chemistry, manufacturing and controls (CMC) activities. If a supply agreement is reached between the companies, we may supply commercial product to Amylin and their exenatide collaboration partner, Eli Lilly and Company, however, there can be no assurance that such a supply agreement will be executed.

     Par Pharmaceutical Partnership

     Under our collaborative arrangement with Par Pharmaceutical Inc. (“Par Pharmaceutical”) executed in October 2004, we granted Par Pharmaceutical the exclusive U.S. distribution and marketing rights to our generic calcitonin-salmon nasal spray. Under the terms of the agreement with Par Pharmaceutical, we will obtain FDA approval, manufacture and supply finished calcitonin-salmon nasal spray product to Par Pharmaceutical. Par Pharmaceutical will distribute the product in the United States. The financial terms of the agreement include milestone payments, product transfer payments for manufactured product and profit sharing upon commercialization.

     In December 2003, we submitted to the FDA an Abbreviated New Drug Application (“ANDA”) for a calcitonin-salmon nasal spray for the treatment of osteoporosis, and in February 2004, the FDA accepted our ANDA for the product for review with no request for additional clinical studies. To date, the FDA has conducted Pre-Approval Inspections (“PAIs”) of both of our nasal spray manufacturing facilities and has informed us the facilities were approved for supplying calcitonin-salmon nasal spray. On September 2, 2005, a citizen’s petition was filed with the FDA requesting that the FDA not approve the ANDA as submitted prior to additional studies for safety and bioequivalence. On October 13, 2005, we filed a response requesting that FDA deny this citizen’s petition on the grounds that no additional information was necessary from a scientific or medical basis and that such additional information is not required under the law. On March 15, 2006, the petitioner submitted an additional request to the FDA in response to our assertions in our October 13, 2005 submission to the FDA. On May 11, 2006 we filed an additional response requesting that the FDA deny the citizen’s petition.

     In addition, Apotex, Inc. (“Apotex”) has filed a generic application for its nasal calcitonin-salmon product with a filing date that has priority over our ANDA for our calcitonin-salmon nasal spray and which prevents us from marketing our product until 180 days after Apotex commences marketing its product. In November 2002, Novartis AG (“Novartis”) brought a patent infringement action against Apotex claiming that Apotex’s nasal calcitonin-salmon product infringes on Novartis’ patents, seeking damages and requesting injunctive relief. That action is still pending. We are unable to predict what, if any, effect the Novartis action will have on Apotex’s ability or plans to commence marketing its product. At this time we are not able to determine whether or not the citizen’s petition will delay the FDA’s approval of our ANDA, nor can we determine when, if at all, Apotex will commence marketing its product.

     On July 10, 2006, we received written notification from the FDA stating that our ANDA for nasal calcitonin-salmon was not approvable at this time. The FDA expressed a concern relating to the potential for immunogenicity that might result from a possible interaction between calcitonin-salmon and chlorobutanol, the preservative in the formulation, although no allergic reactions have been observed in any of the clinical trials conducted by us and other existing marketed nasal spray products contain chlorobutanol as the preservative. On September 29, 2006, we announced that we had submitted a complete response to the FDA’s Office of Generic Drugs regarding the potential for immunogenicity that might result from a possible interaction between calcitonin-salmon and chlorobutanol. The FDA has accepted our submission for review, indicating that the generic division of the FDA has maintained jurisdiction of our filing. Furthermore, the FDA has indicated that our response is classified as a major amendment to the ANDA, and we therefore expect that the FDA will take at least six months to complete its review of our submission. If we are not successful at keeping this application as an ANDA then a 505(b)(2) NDA may be pursued or the application may be withdrawn. At this time we are not able to determine when, if at all, the Company’s calcitonin product will receive marketing approval from the FDA.

     Our formulation of calcitonin-salmon nasal spray was specifically developed to be similar to Novartis’ currently marketed calcitonin-salmon nasal spray, Miacalcin^®, in order to submit the application as an ANDA. Thus, our formulation does not utilize our

advanced tight junction drug delivery technology, which is currently being used in development of our proprietary pipeline of peptide and protein therapeutics.

     Merck Partnership/PYY

     The strategic collaboration that we entered into with Merck in September 2004 for PYY was terminated on March 1, 2006. Under the agreement, Nastech reacquired its rights in the PYY program.

     We have continued PYY product development on our own, and on August 14, 2006, we announced the initiation of a dose ranging study designed to evaluate the pharmacokinetic parameters, appetite, food intake and safety of various doses of Nastech’s PYY nasal spray in obese subjects.

     RNAi Technology and Intellectual Property Acquisitions

     We are also applying our drug delivery technology to a promising new class of therapeutics based on RNA interference (“RNAi”). Small interfering RNAs (“siRNAs”) are double-stranded RNA molecules that are able to silence specific genes and reduce the amount of protein these genes produce. The specific protein may be involved in causing a disease or necessary for the replication of a pathogenic virus. The therapeutic use of RNAi in this manner requires the ability to deliver siRNA-based drugs inside the cells where the target proteins are produced. We have continued our research and development program to enhance the delivery of this potential new class of therapeutic drugs and have strengthened our RNAi development strategy through the acquisition of key technologies, IP, and licensing agreements.

     Alnylam. We entered into a license agreement on July 20, 2005 with Alnylam Pharmaceuticals, Inc. (“Alnylam”), a biopharmaceutical company focused on developing RNAi based drugs, pursuant to Alnylam’s InterfeRx™ licensing program. Under the license, we acquired the exclusive rights to discover, develop and commercialize RNAi therapeutics directed against TNF-alpha, a protein associated with inflammatory diseases including rheumatoid arthritis and certain chronic diseases. Under our agreement with Alnylam, we paid an initial license fee to Alnylam, and we are obligated to pay annual and milestone fees and royalties on sales of any products covered by the license agreement.

     Galenea Corp./MIT. We have expanded our RNAi pipeline by initiating an RNAi therapeutics program targeting influenza and respiratory diseases. In connection with this new program, in February 2006 we acquired Galenea’s RNAi IP estate and other technologies. The IP acquired from Galenea includes patent applications licensed from MIT that have early priority dates in the antiviral RNAi field focused on viral respiratory infections, including influenza, rhinovirus, and other respiratory diseases. We also acquired Galenea’s research and IP relating to pulmonary drug delivery technologies for siRNA. Additionally, we assumed Galenea’s awarded and pending grant applications from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, and the Department of Defense to support the development of RNAi-based antiviral drugs.

     RNAi-based therapeutics offer potentially effective treatments for a future influenza pandemic, which is an urgent global concern. This program complements our current TNF-alpha RNAi program targeting inflammation, since a consequence of influenza infection can be life-threatening respiratory and systemic inflammation, caused by excess TNF-alpha production.

     The lead siRNA product candidate licensed from Galenea, G00101, has demonstrated efficacy against multiple influenza strains, including avian flu strains (H5N1) in animals. The development of siRNA targeting sequences that are highly conserved across all flu genomes, including avian and others having pandemic potential, have a reduced potential of drug resistance and is a novel approach to the development of new therapies against influenza viruses. We believe G00101 represents a first-in-class approach to fight influenza and is one of the most advanced anti-influenza compounds based on RNAi, although there can be no assurance that clinical trials will be successful or that our research efforts with respect to G00101 or other siRNA targeting sequences will lead to commercial products. G00101 can be administered by inhalation to maximize delivery to the lung epithelium and has the potential to be delivered to the nasal cavity using our tight junction modulation technology to prevent or abate early viral infections. The product is being designed for ease of use by patients and for long-term stability, both essential for stockpiling the product for rapid mobilization during a flu epidemic.

     Government Grants. On August 29, 2006, we announced that the NIH awarded us a Phase 1 Small Business Innovation Research (SBIR) grant to further our siRNA therapeutics to prevent and treat influenza. The grant, in the amount of $0.4 million, was received

by us in September 2006 and recognized as grant revenue during the three month period ended September 30, 2006. On September 26, 2006, we announced that the NIH awarded us a $1.9 million Research Project (R01) grant to prevent and treat influenza.

     Cash Position and Recent Financings

     As of September 30, 2006, we had approximately $56.4 million in cash, cash equivalents and short-term investments, including approximately $2.2 million in restricted cash and short-term investments. We believe, although there can be no assurance, that our current cash position provides us with adequate working capital for at least the next 12 months, or longer depending upon the degree to which we exploit our various current opportunities that are in the pipeline and the success of our collaborative arrangements. This belief is based, in part, on the assumption that we have completed and are planning to enter into various collaborations to accelerate our research and development programs which will provide us with additional financing. To the extent these collaborations do not proceed as planned, we may be required to reduce our research and development activities or, if necessary and possible, raise additional capital from new investors or in the public markets.

     In June 2004, we completed the sale of 1,136,364 shares of our common stock, and warrants to purchase up to 511,364 shares of common stock at an exercise price of $14.40 per share, pursuant to our $30 million shelf registration statement that was declared effective by the SEC on January 14, 2004. The offering resulted in gross proceeds of approximately $12.5 million to us prior to the deduction of fees and commissions of $229,000. The warrants vested on December 25, 2004, and are exercisable until June 25, 2009. At September 30, 2006, the amount remaining available on this shelf registration statement was approximately $10.1 million. On October 19, 2006, we filed a shelf registration statement on Form S-3 for $125.0 million of common stock which includes the remaining $10.1 million balance from one of our previous shelf registration statements. As of the date of this filing, the new $125.0 million shelf has not been declared effective by the SEC.

     In December 2004, we completed the public offering of 4,250,000 shares of our common stock at a price of $13.50 per share pursuant to our $80 million shelf registration statement that was declared effective by the SEC on October 8, 2004. The offering resulted in gross proceeds of approximately $57.4 million to us, prior to the deduction of fees and commissions of $4.5 million. In August 2005, we completed a public offering of 1,725,000 shares of our common stock at a price of $13.50 per share pursuant to our $80 million shelf registration statement and a $0.7 million post effective amendment filed on August 25, 2005 pursuant to Rule 462(b) of the Securities Act. The offering resulted in gross proceeds of approximately $23.3 million to the Company, prior to the deduction of fees and commissions of approximately $1.7 million. At September 30, 2006, no shares remained available on this shelf registration statement.

Critical Accounting Policies and Estimates

     We prepare our consolidated financial statements in conformity with U.S. generally accepted accounting principles. As such, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the periods presented. Actual results could differ significantly from those estimates under different assumptions and conditions. We believe that the following discussion addresses our most critical accounting estimates which are those that are most important to the portrayal of our financial condition and results of operations and which require our most difficult and subjective judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Other key estimates and assumptions that affect reported amounts and disclosures include depreciation and amortization, inventory reserves, asset impairments, requirements for and computation of allowances for doubtful accounts, allowances for product returns, expense accruals and goodwill valuation. We also have other policies that we consider key accounting policies; however, these policies do not meet the definition of critical accounting estimates, because they do not generally require us to make estimates or judgments which are difficult or subjective.

Revenue Recognition

     Most of our revenues result from research and licensing arrangements. These research and licensing arrangements may include upfront non-refundable payments, development milestone payments, payments for research and development services performed, revenue from product manufacturing and product sales royalties or revenue. Our revenue recognition policies are based on the requirements of SEC Staff Accounting Bulletin No. 104 “Revenue Recognition,” and, for contracts with multiple deliverables, we allocate arrangement consideration based on the fair value of the elements under guidance from Emerging Issues Task Force Issue 00-

21 (“EITF 00-21”), “Revenue Arrangements with Multiple Deliverables.” Under EITF 00-21, revenue arrangements with multiple deliverables may be divided into separate units of accounting such as product development and contract manufacturing. Revenue is allocated to these units based upon relative fair values with revenue recognition criteria considered separately for each unit.

     Nonrefundable upfront technology license fees, for product candidates where we are providing continuing services related to product development, are deferred and recognized as revenue over the development period or as we provide the services required under the agreement. The ability to estimate total development effort and costs can vary significantly for each product candidate due to the inherent complexities and uncertainties of drug development. If we cannot estimate the costs to complete development, but can estimate an expected NDA filing date, we will recognize license fee revenue ratably through the NDA filing date. If we are unable to reasonably estimate either total costs to complete development or an expected NDA filing date (performance period), we will defer revenue recognition until one of those estimates can be made or the project is discontinued.

     Milestones, in the form of additional license fees, typically represent nonrefundable payments to be received in conjunction with the achievement of a specific event identified in the contract, such as initiation or completion of specified clinical development activities. We believe that a milestone represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on our part. We recognize such milestones as revenue when they become due and collection is reasonably assured. When a milestone does not represent the culmination of a distinct earnings process, revenue is either recognized when the earnings process is deemed to be complete or in a manner similar to that of an upfront technology license fee.

     The timing and amount of revenue that we recognize from licenses of technology, either from upfront fees or milestones where we are providing continuing services related to product development, is dependent upon our estimates of filing dates or development costs. As product candidates move through the development process, it is necessary to revise these estimates to consider changes to the product development cycle, such as changes in the clinical development plan, regulatory requirements, or various other factors, many of which may be outside of our control. The impact on revenue of changes in our estimates and the timing thereof, is recognized prospectively, over the remaining estimated product development period.

     Royalty revenue is generally recognized at the time of product sale by the licensee.

     Revenue from research and development services performed is generally received for services performed under collaboration agreements, and is recognized as services are performed. Payments received in excess of amounts earned are recorded as deferred revenue.

     Product sales revenue is recognized when the manufactured goods are shipped to the purchaser and title has transferred.

     Under the guidance of EITF Issue 01-14, reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses.

     Government grant revenue is recognized during the period qualifying expenses are incurred for the research that is performed as set forth under the terms of the grant award agreements, and when there is reasonable assurance that we will comply with the terms of the grant and that the grant will be received.

     Stock-Based Compensation

     On January 1, 2006, we adopted Statement of Financial Accounting Standards No. 123R, “Share-Based Payment (Revised 2004),” which requires the measurement and recognition of compensation for all stock-based awards made to employees and directors including stock options and employee stock purchases under a stock purchase plan based on estimated fair values. SFAS 123R supersedes previous accounting under Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” for periods beginning in fiscal 2006. In March 2005, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 107 relating to application of SFAS 123R. We have applied the provisions of SAB 107 in our adoption of SFAS 123R.

     We adopted SFAS 123R using the modified prospective transition method, which requires the application of the accounting standard as of January 1, 2006. In accordance with the modified prospective transition method, our condensed consolidated financial statements for periods prior to January 1, 2006 have not been restated to reflect this change. Stock-based compensation recognized during current periods is based on the value of the portion of the stock-based award that will vest during the period, adjusted for

expected forfeitures. Stock-based compensation recognized in our condensed consolidated financial statements for the nine months ended September 30, 2006 includes compensation cost for stock-based awards granted prior to, but not fully vested as of, December 31, 2005 and stock-based awards granted subsequent to December 31, 2005. The compensation cost for awards granted prior to January 1, 2006 is based on the grant date fair value estimated in accordance with the pro forma provisions of SFAS 123 while awards granted after December 31, 2005 follow the provisions of SFAS 123R to determine the grant date fair value and compensation cost. Compensation cost for all stock-based awards is recognized using the straight-line method over the vesting period.

     The adoption of SFAS 123R resulted in a cumulative benefit from accounting change of $291,000 as of January 1, 2006, which reflects the net cumulative impact of estimating future forfeitures in the determination of period expense for restricted stock awards, rather than recording forfeitures when they occur as previously permitted.

     Upon adoption of SFAS 123R we continued to use the Black-Scholes option pricing model as our method of valuation for stock-based awards. Our determination of the fair value of stock-based awards on the date of grant using an option pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to the expected life of the award, our expected stock price volatility over the term of the award and actual and projected exercise behaviors. Although the fair value of stock-based awards is determined in accordance with SFAS 123R and SAB 107, the Black-Scholes option pricing model requires the input of highly subjective assumptions, and other reasonable assumptions could provide differing results. The adoption of SFAS 123R will result in recognition of additional non-cash stock-based compensation expense and, accordingly, will increase net loss in amounts which likely will be considered material. Our stock-based compensation philosophy did not change with the adoption of SFAS 123R. Since mid-2004, we have granted options and restricted stock to executive management and directors, and restricted stock to employees. There was no acceleration of vesting associated with the adoption of SFAS 123R. Our total unrecognized compensation cost related to unvested stock options was approximately $3.9 million at September 30, 2006, and we expect to recognize this cost over a weighted average period of approximately 1.5 years.

     Income Taxes

     A critical estimate is the full valuation allowance for deferred taxes that was recorded based on the uncertainty that such tax benefits will be realized in future periods. To the extent we achieve profitability such deferred tax allowance would be reversed.

     Research and Development Costs

     All research and development (“R&D”) costs are charged to operations as incurred. Our R&D expenses consist of costs incurred for internal and external R&D. These costs include direct and research-related overhead expenses. Clinical trial expenses, which are included in R&D expenses, represent obligations resulting from our contracts with various clinical research organizations in connection with conducting clinical trials for our product candidates. We recognize expenses for these contracted activities based on a variety of factors, including actual and estimated labor hours, clinical site initiation activities, patient enrollment rates, estimates of external costs and other activity-based factors. We believe that this method best approximates the efforts expended on a clinical trial with the expenses we record. We adjust our rate of clinical expense recognition if actual results differ from our estimates.

     When we acquire intellectual properties from others, the purchase price is allocated, as applicable, between In-Process Research and Development (“IPR&D”), other identifiable intangible assets and net tangible assets. Our policy defines IPR&D as the value assigned to those projects for which the related products have not yet reached technological feasibility and have no alternative future use. Determining the portion of the purchase price allocated to IPR&D requires us to make significant estimates. The amount of the purchase price allocated to IPR&D is determined by estimating the future cash flows of each project of technology and discounting the net cash flows back to their present values. The discount rate used is determined at the acquisition date, in accordance with accepted valuation methods, and includes consideration of the assessed risk of the project not being developed to a stage of commercial feasibility. Amounts recorded as IPR&D are charged to R&D expense upon acquisition.

Results of Operations

Revenue and cost of revenue

     Our revenue consists of product sales and license and research fees. Revenue totaled approximately $5.5 million and $23.7 million for the three month and nine month periods ended September 30, 2006, increases of approximately $4.3 million and $17.5 million over the prior year periods. The increases are due primarily to the revenue recognized under the collaboration agreement with P&G including a portion of the $10.0 million license fee, revenue for R&D services performed and recognition of a $7.0 million milestone

payment. In addition, in the 2006 periods we recognized approximately $3.7 million in deferred license fees as a result of the termination of our collaboration with Merck and revenue earned under contracts with other collaborative partners over their estimated remaining development periods. Estimated development periods may be revised over time based upon changes in clinical development plans, regulatory requirements or other factors, many of which may be out of our control. We recognized a $2.0 million payment from Questcor relating to the FDA approval of our Nascobal® nasal spray product in the nine months ended September 30, 2005.

     Our product revenue consists of sales of Nascobal® nasal gel and nasal spray. During the three and nine month periods ended September 30, 2006, we recognized approximately $32,000 and $624,000 of product revenue, respectively. During the interim periods ended September 30, 2005, we did not produce or ship any Nascobal® nasal gel or nasal spray under the supply agreement with Questcor. Effective in October 2005, the distribution of our Nascobal® nasal gel and spray products has been transferred from Questcor to QOL. Cost of product revenue as a percent of product revenue was approximately 41% and 50% for the three and nine month periods ended September 30, 2006. We expect to continue to receive product revenue under the QOL supply agreement.

     The dollar and percentage increases in revenue may not be indicative of performance in future periods. Additional information on our revenue is as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2005				2006				2005				2006
		(dollars in thousands)
Product revenue, net		$	—			$	32			$	—			$	624
License and research fees
Questcor FDA approval milestone payment			—				—				2,000				—
Revenue recognized under the terminated Merck agreements			913				—				2,789				3,741
Revenue recognized under the P&G agreement			—				4,752				—				17,660
Other license and research fees			310				378				1,366				1,266
License and research fees, total			1,223				5,130				6,155				22,667
Government grant revenue			—				383				—				383
Total revenue		$	1,223			$	5,545			$	6,155			$	23,674
Dollar increase						$	4,322							$	17,519
Percentage increase							353	%							285	%

Research and development

     Research and development expense consists primarily of salaries and other personnel-related expenses, costs of clinical trials, consulting and other outside service, laboratory supplies, facilities costs, FDA filing fees, other costs and, in 2006 purchased In-Process Research and Development expenses (“IPR&D”). Excluding purchased IPR&D, research and development expense by project as a percentage of total research and development project expense, and total research and development expense, are as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2005				2006				2005				2006
		(dollars in thousands)
PTH(1-34)			17	%			33	%			15	%			29	%
Tight Junctions and RNAi			29	%			21	%			25	%			24	%
Insulin			—				10	%			—				11	%
Influenza			—				9	%			—				8	%
Calcitonin			18	%			5	%			30	%			7	%
Peptide YY			22	%			4	%			16	%			4	%
Other R&D projects (1)			14	%			18	%			14	%			17	%
			100	%			100	%			100	%			100	%
Total R&D expense		$	8,099			$	10,483			$	22,559			$	26,956	(2)
Dollar increase							2,384								4,397
Percentage increase							29	%							19	%

     The 29% increase in research and development expense in the three month period ending September 30, 2006 compared to the same period in 2005 resulted primarily from the following:

	•		Personnel-related expenses increased by approximately 44% to $4.9 million compared to $3.4 million in the prior year period due to an increase in headcount in support of our research and development programs and due to an increase of approximately $0.4 million in non-cash stock compensation. R&D headcount increased from 100 at September 30, 2005 to 151 at September 30, 2006.
	•		Costs of clinical trials, consulting, outside services and laboratory supplies increased by approximately 23% to $3.2 million compared to $2.6 million in the prior year period due to purchases of active pharmaceutical ingredients used in our PTH and RNAi programs and clinical trials initiated for our PYY and insulin programs.
	•		Facilities and equipment costs increased approximately 67% to $2.0 million from $1.2 million in the prior year period due to rent and related expenses on additional space leased and an increase in depreciation of equipment resulting from capital expenditures to acquire needed technical capabilities and to support increased capacity.
	•		Research and development administrative expenses decreased by approximately 56% to $0.4 million from $0.9 million in the prior year period due to patent license fees incurred in 2005.

The 19% increase in research and development expense (excluding purchased IPR&D) in the nine month period ending September 30, 2006 compared to the same period in 2005 resulted primarily from the following:

	•		Personnel-related expenses increased by approximately 48% to $13.9 million compared to $9.4 million in the prior year period due to an increase in headcount in support of our research and development programs and due to an increase of approximately $1.3 million in non-cash stock compensation.
	•		Costs of clinical trials, consulting, outside services and laboratory supplies decreased by approximately 15% to $7.1 million compared to $8.4 million in the prior year period as the 2005 period included significant clinical trial expenses for calcitonin.
	•		Facilities and equipment costs increased approximately 43% to $5.0 million from $3.5 million in the prior year period due to rent and related expenses on additional space leased and an increase in depreciation of equipment resulting from capital expenditures to acquire needed technical capabilities and to support increased capacity.
	•		Research and development administrative expenses decreased by approximately 31% to $0.9 million from $1.3 million in the prior year period due to patent license fees incurred in 2005.

     Purchased IPR&D expenses, excluded from the table above but included in total research and development expense, were approximately $4.1 million in the nine months ended September 30, 2006 compared to zero in the prior year period and related to purchased in-process research and development costs from Galenea Corp. in the field of RNAi related to influenza.

     We expect a continued increase in research and development expense from the amounts presented in the table above which exclude purchased IPR&D expenses in the foreseeable future as we continue to expand our research and development activities. These expenditures are subject to uncertainties in timing and cost to completion. We test compounds in numerous preclinical studies for safety, toxicology and efficacy. We then conduct early stage clinical trials for each drug candidate. If we are not able to engage a collaboration partner prior to the commencement of later stage clinical trials, or if we decide to pursue a strategy of maintaining commercialization rights to a program, we may fund these trials ourselves. As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain products in order to focus our resources on more promising products. Completion of clinical trials by us and our collaboration partners may take several years or more, but the length of time varies substantially according to the type, complexity, novelty and intended use of a drug candidate. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including:

	•		the number of sites included in the clinical trials;
	•		the length of time required to enroll suitable patient subjects;
	•		the number of patients that participate in the trials;
	•		the duration of patient follow-up that seems appropriate in view of results; and
	•		the number and complexity of safety and efficacy parameters monitored during the study.

     None of our current product candidates utilizing our intranasal drug delivery technology has received FDA or foreign regulatory marketing approval, except Nascobal® nasal gel and nasal spray. In order to achieve marketing approval, the FDA or foreign regulatory agencies must conclude that our and our collaboration partners’ clinical data establishes the safety and efficacy of our drug candidates. Furthermore, our strategy includes entering into collaborations with third parties to participate in the development and commercialization of our products. In the event that the collaboration partner has control over the development process for a product, the estimated completion date would largely be under control of such partner. We cannot forecast with any degree of certainty how such collaboration arrangements will affect our development spending or capital requirements.

     As a result of the uncertainties discussed above, we are often unable to determine the duration and completion costs of our research and development projects or when and to what extent we will receive cash inflows from the commercialization and sale of a product.

Sales and marketing

     Sales and marketing expense consists primarily of salaries and other personnel-related expenses, consulting, sales materials, trade shows and advertising. Total sales and marketing expense and dollar and percentage changes are as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2005				2006				2005				2006
		(dollars in thousands)
Total sales and marketing expense		$	345			$	505			$	963			$	1,335
Dollar increase							160								372
Percentage increase							46	%							39	%

     The increases in the three and nine month periods ended September 30, 2006 over the same periods in 2005 resulted primarily from increased business development personnel costs and increases in spending on market research, conference related activities, non-cash stock compensation and business development efforts. We expect sales and marketing costs, which includes business development staff and activities, to increase moderately in the foreseeable future to support activities associated with partnering our drug candidates.

General and administrative

     General and administrative expense consists primarily of salaries and other personnel-related expenses to support our research and development activities, amortization of non-cash deferred stock option and restricted stock compensation for general and administrative personnel and non-employee board members, professional fees such as accounting and legal, corporate insurance and facilities costs. Total general and administrative expense and dollar and percentage changes are as follows:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2005				2006				2005				2006
		(dollars in thousands)
Total general and administrative expense		$	2,019			$	2,943			$	6,949			$	9,194
Dollar increase							924								2,245
Percentage increase							46	%							32	%

     The increases in the three and nine month periods ended September 30, 2006 over the same periods in 2005 were due primarily to increases in non-cash stock compensation of $0.3 million and $1.1 million, respectively. The remaining increases were due to increased compensation-related expenses related to the hiring of additional personnel supporting R&D and compliance activities, legal fees, corporate insurance and annual and board meeting expenses. We expect general and administrative expenses to remain stable or to increase in the foreseeable future, depending on the growth of our research and development and other corporate activities.

Interest Income

     The following table sets forth information on interest income, average funds available for investment and average interest rate earned:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2005				2006				2005				2006
		(dollars in thousands)
Interest income		$	496			$	751			$	1,321			$	2,107
Average funds available for investment		$	59,800			$	60,800			$	61,400			$	59,500
Average interest rate, annualized			3.3	%			5.1	%			2.9	%			4.7	%

     The increase in interest income in the three and nine month periods ended September 30, 2006 over the 2005 periods was due primarily to increases in prevailing market interest rates in the current year period.

Interest Expense

     We incur interest expense on our capital leases and, formerly, on notes payable. The following table sets forth information on interest expense, average borrowings and average interest rate earned:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2005				2006				2005				2006
		(dollars in thousands)
Interest expense		$	75			$	162			$	265			$	405
Average borrowings under capital leases and notes payable		$	4,300			$	7,600			$	5,400			$	6,300
Average interest rate, annualized			7.0	%			8.5	%			7.0	%			8.6	%

     The increase in interest expense in the three and nine month periods ended September 30, 2006 is due to a combination of higher average borrowing rates and amounts borrowed during the 2006 periods compared to the 2005 periods. Interest rates on outstanding borrowings under the GE Capital leases range from approximately 8% to approximately 11%.

Liquidity and Capital Resources

Cash Requirements

     Our capital requirements consist primarily of the need for working capital, including funding research and development activities and capital expenditures for the purchase of equipment. From time to time, we may also require capital for investments involving acquisitions and strategic relationships. We have an accumulated deficit of approximately $131.8 million as of September 30, 2006, and expect additional operating losses in the foreseeable future as we continue to expand our research and development activities. In addition, we are planning to enter into various collaborations in furtherance of our research and development programs. To the extent these collaborations do not proceed as planned, we may be required to reduce our research and development activities or, if necessary and possible, raise additional capital from new investors or in the public markets.

Sources and Uses of Cash

     We have financed our operations primarily through the sale of common stock and warrants through private placements and in the public markets, revenues received from our collaboration partners, and to a lesser extent equipment financing facilities and notes payable.

     In December 2003, we filed a shelf registration statement with the SEC, which was declared effective by the SEC in January 2004, pursuant to which we may issue common stock or warrants, up to an aggregate of $30 million. In September 2004, we filed another shelf registration statement with the SEC, which was declared effective by the SEC in October 2004, pursuant to which we may issue common stock, warrants or debt securities, up to an aggregate of $80 million. These shelf registration statements enable us to raise capital from the offering of securities covered by the shelf registration statements, as well as any combination thereof, from time to time and through one or more methods of distribution, subject to market conditions and our cash needs.

     In June 2004, we completed the sale of 1,136,364 shares of our common stock, and warrants to purchase up to 511,364 shares of common stock at an exercise price of $14.40 per share, pursuant to our $30 million effective shelf registration statement. The offering resulted in gross proceeds of approximately $12.5 million to us prior to the deduction of fees and commissions of $229,000. The warrants vested on December 25, 2004, and are exercisable until June 25, 2009. At September 30, 2006, the amount remaining available on this shelf registration statement was approximately $10.1 million. In December 2004, we completed the public offering of 4,250,000 shares of our common stock at a price of $13.50 per share pursuant to our $80 million shelf registration statement that was declared effective by the SEC in October 2004. The offering resulted in gross proceeds of approximately $57.4 million to us, prior to the deduction of fees and commissions of $4.5 million. On August 30, 2005, we completed a public offering of 1,725,000 shares of our common stock at a price of $13.50 per share pursuant to our $80 million shelf registration statement and a $0.7 million post effective amendment filed on August 25, 2005 pursuant to Rule 462(b) of the Securities Act. The offering resulted in gross proceeds of approximately $23.3 million to the Company, prior to the deduction of fees and commissions of approximately $1.7 million. At September 30, 2006, the amount remaining available on this shelf registration statement was zero. On October 19, 2006, we filed a shelf registration statement on Form S-3 for $125.0 million of common stock which includes the remaining $10.1 million balance from one of our previous shelf registration statements. As of the date of this filing, the new $125.0 million shelf has not been declared effective by the SEC.

     In the nine months ended September 30, 2006, we received approximately $5.5 million from the exercise of common stock warrants and approximately $3.1 million from the exercise of common stock options.

     Our research and development efforts and collaborative arrangements with our partners enable us to generate contract research revenues, milestone payments, license fees, royalties and manufactured product sales for us.

	•		Under our collaborative arrangement with P&G, we received an initial cash payment of $10 million in February 2006. The $10 million initial payment has been recorded as deferred revenue and is being amortized into revenue over the estimated development period. In the three months ended June 30, 2006 we received and recognized a $7.0 million milestone payment from P&G. The arrangement includes the potential for additional contractual payments of up to $15 million during the remainder of 2006. In total, contractual payments could reach $577 million over the life of the project depending upon the successful completion of specified development, regulatory and commercialization goals, although there can be no assurance that any such milestones will be achieved. Under our agreement with P&G, we are eligible to receive double-digit patent-based royalties, with the rate escalating upon the achievement of certain sales levels.
	•		Under our collaborative arrangement with Merck, we received an initial cash payment of $5 million in October 2004. The $5 million initial payment was being amortized over the estimated development period until the collaboration with Merck for PYY was terminated on March 1, 2006, at which time the $3.7 million balance of the unamortized license payment was recognized as revenue. Under the agreement, Nastech reacquired its rights in the PYY program.
	•		Under our collaborative arrangement with Par Pharmaceutical, we received an initial cash payment in October 2004 which was amortized over the estimated development period.
	•		Under our supply agreement with Questcor, in February 2005 we received and recognized a payment of $2 million from Questcor upon FDA approval of a New Drug Application for the Nascobal® nasal spray product. On October 17, 2005, with our consent, Questcor assigned all of its rights and obligations under the Questcor Asset Purchase and Supply Agreements dated June 2003 to QOL. We received $2.0 million from Questcor on October 19, 2005 in consideration for our consent to the assignment and in connection with us entering into an agreement with QOL which modified certain terms of the Asset Purchase and Supply Agreements. The $2.0 million is being recognized ratably over the five-year life of the QOL agreement. QOL has assumed Questcor’s obligation to pay us an additional $2.0 million contingent upon issuance of a U.S. patent for the Nascobal® nasal spray product.

     Total sources and uses of cash for the periods indicated are as follows:

		Nine Months Ended
		September 30,
		2005				2006
		(dollars in thousands)
Cash used in operating activities		$	(23,369	)		$	(7,978	)
Cash used in investing activities			(14,790	)			(9,171	)
Cash provided by financing activities			28,273				11,461
Net decrease in cash and cash equivalents		$	(9,886	)		$	(5,688	)

     Our operating activities used cash of $8.0 million in the first nine months of 2006 compared to $23.4 million in the first nine months of 2005. Cash used in operating activities relates primarily to funding net losses, adjusted by changes in balance sheet account balances and partially offset by non-cash charges related to depreciation and amortization of property and equipment and stock compensation. Deferred revenue provided approximately $3.2 million in operating cash in the current period due primarily to the recording of a $10 million 2006 receipt from P&G as deferred revenue, compared to using approximately $1.6 million in the prior year period as a result of amortization of Merck and Par deferred revenue. We received a $383,000 government grant in the 2006 period compared to zero in the 2005 period. We expect to use cash for operating activities in the foreseeable future as we continue our research and development activities.

     Our investing activities used cash of $9.2 million in the first nine months of 2006 compared to $14.8 million in the first nine months of 2005. Changes in cash from investing activities are due primarily to purchases of short-term investments, net of maturities and investments in property and equipment. We expect to continue to invest in our research and development infrastructure, including the purchase of equipment to support our research and development activities.

     Our financing activities provided cash of $11.5 million in the first nine months of 2006 compared to providing cash of $28.3 million in the first nine months of 2005. Cash provided in the 2006 period primarily resulted from proceeds from the exercise of common stock options of approximately $3.1 million and common stock warrants of approximately $5.5 million. During the nine months ended September 30, 2006, we drew down approximately $6.3 million on a capital lease facility. During the nine months ended September 30, 2005, we repaid approximately $8.4 million on our Revolving Line of Credit and terminated the facility, and we drew down approximately $2.9 million on a capital lease facility. As a result of the loan payoff in the 2005 period, our restricted cash balance decreased by $8.0 million.

Liquidity

     We had a working capital (current assets minus current liabilities) surplus of $48.9 million as of September 30, 2006 and $55.2 million as of December 31, 2005. As of September 30, 2006, we had approximately $56.4 million in cash, cash-equivalents and short-term investments, including approximately $2.2 million in restricted cash and short-term investments. Our cash position for the nine months ended September 30, 2006 decreased by approximately $5.7 million. During the comparable 2005 period, our cash position decreased by approximately $9.9 million. Revenue recognized in the nine months ended September 30, 2006 was higher than that of the prior year period and the current period net loss was lower than that of the prior year period, primarily due to the uneven timing of revenue recognition of contractual payments, period and higher expenses in 2006 compared to 2005. Additionally we had higher levels of warrant and option exercises in 2006 compared to 2005. In light of these factors, we caution that the current period results may not be indicative of performance in future periods. We believe, although there can be no assurance, that our current cash position provides us with adequate working capital for at least the next 12 months, or longer depending upon the degree to which we exploit our various current opportunities that are in the pipeline and the success of our collaborative arrangements. This belief is based, in part, on the assumption that we have completed and are planning to enter into various collaborations to accelerate our research and development programs which will provide us with additional financing. To the extent these collaborations do not proceed as planned, we may be required to reduce our research and development activities or, if necessary and possible, raise additional capital from new investors or in the public markets.

     As of September 30, 2006, the unused portion of our 2006 capital lease credit line of $7.5 million for financing equipment and leasehold assets was approximately $1.3 million.

Contractual Obligations

     Our contractual obligations have changed since December 31, 2005 to September 30, 2006 as follows:

	•		At September 30, 2006 our operating lease obligations increased to approximately $30.4 million (through February 2016) from approximately $19.3 million at December 31, 2005. This is due to a new facility lease signed in 2006 adding approximately $12.6 million in rental payments through February 2016, partially offset by approximately $1.5 million in rents paid during the nine months ended September 30, 2006.
	•		Our capital lease obligations increased by approximately $4.9 million to approximately $11.2 million (including future interest payments) at September 30, 2006 due to approximately $7.5 million (including approximately $1.2 million of future interest payments) in new leases funded offset by approximately $2.6 million in payments (including $0.4 million in interest payments made during the nine months ended September 30, 2006.
	•		Our purchase obligations increased by approximately $2.9 million from approximately $0.6 million to approximately $3.5 million at September 30, 2006 due to purchase order activity (primarily for PTH(1-34)) during the nine months ended September 30, 2006.

Off-Balance Sheet Arrangements

     As of September 30, 2006, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

     We are exposed to financial market risk resulting from changes in interest rates. We do not engage in speculative or leveraged transactions, nor do we utilize derivative financial instruments. We invest in interest-bearing instruments that are classified as cash and cash equivalents, restricted cash and short-term investments. Our investment policy is to manage our total invested funds to preserve principal and liquidity while maximizing the return on the investment portfolio through the full investment of available funds. We invest in debt instruments of U.S. Government agencies and, prior to October 5, 2005, also invested in high quality corporate issues (Standard & Poors double “AA” rating and higher). Unrealized gains or losses related to fluctuations in interest rates are reflected in other comprehensive income or loss. Based on our cash and cash equivalents, restricted cash and short-term investments balances at September 30, 2006, a 100 basis point increase or decrease in interest rates would result in an increase or decrease of approximately $550,000 to interest income on an annual basis.

ITEM 4 – CONTROLS AND PROCEDURES

     (a) Disclosure Controls and Procedures. As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out an evaluation, under the supervision and with the participation of senior management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of its disclosure controls and procedures. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures are effective for gathering, analyzing and disclosing the information that the Company is required to disclose in reports filed under the Securities Exchange Act of 1934, as amended.

     (b) Internal Control Over Financial Reporting. There have been no changes in the Company’s internal controls over financial reporting or in other factors during the fiscal quarter ended September 30, 2006, that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting subsequent to the date the Company carried out its most recent evaluation.

PART II – OTHER INFORMATION

ITEM 1A – RISK FACTORS

     The disclosures in Item 1A — Risk Factors in our annual report on Form 10-K for the year ended December 31, 2005 (the “10-K”) under the captions “we are dependent on our collaborative arrangement with third parties for a substantial portion of our revenue, and our development and commercialization activities may be delayed or reduced if we fail to negotiate or maintain successful collaborative arrangements” on page 26 of the 10-K, is hereby supplemented by adding the following at the end of such disclosure:

     We are also dependent on contracts with government agencies to fund certain product development candidates. There is currently work being performed and reimbursed by governmental agencies for the development of one of our drug candidates. Any contracts with governmental agencies may not be completed on terms favorable to us, or at all, and any revenues under such contracts may not cover the development costs of our programs. These grants are subject to review and audit by the federal government and any such audit could lead to requests for reimbursement for any expenditure disallowed under the terms of the grant. Additionally, any noncompliance with the terms of these grants could lead to loss of current or future awards.

ITEM 6 – EXHIBITS

     The exhibits required by this item are set forth in the Exhibit Index attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized, in Bothell, State of Washington, on November 1, 2006.

EXHIBIT INDEX

Exhibit
No.		Description
2.1		Agreement and Plan of Reorganization, dated August 8, 2000, among the Company, Atossa Acquisition Corporation, a Delaware corporation and wholly-owned subsidiary of the Company, and Atossa HealthCare, Inc. (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K dated August 8, 2000, and incorporated herein by reference).
2.2		Asset Purchase Agreement, dated September 30, 2002, with Schwarz Pharma, Inc.(filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K dated September 30, 2002 and incorporated herein by reference).
3.1		Restated Certificate of Incorporation of the Company dated July 20, 2005 (filed as Exhibit 3.1 to our Current Report on Form 8-K dated July 20, 2005, and incorporated herein by reference).
3.2		Amended and Restated Bylaws of the Company dated August 11, 2004 (filed as Exhibit 3.10 to our Registration Statement on Form S-3, File No. 333-119429, and incorporated herein by reference).
4.1		Investment Agreement, dated as of February 1, 2002, by and between the Company and Pharmacia & Upjohn Company (filed as Exhibit 4.1 to the Company Current Report on Form 8-K dated February 1, 2002 and incorporated herein by reference).
4.2		Rights Agreement, dated February 22, 2000, between the Company and American Stock Transfer & Trust Company as Rights Agent (filed as Exhibit 1 to our Current Report on Form 8-K dated February 22, 2000 and incorporated herein by reference).
4.3		Securities Purchase Agreement dated as of June 25, 2004 (filed as Exhibit 99.2 to our Current Report on Form 8-K dated June 25, 2004 and incorporated herein by reference).
4.4		Form of Warrant (filed as Exhibit 99.3 to the Company’s Current Report on Form 8-K dated June 25, 2004 and incorporated herein by reference).
10.1		Lease Agreement for facilities at 45 Davids Drive, Hauppauge, NY, effective as of July 1, 2005 (filed as Exhibit 10.30 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 and incorporated herein by reference).
10.2		Lease Agreement, dated April 23, 2002, with Phase 3 Science Center LLC, Ahwatukee Hills Investors LLC and J. Alexander’s LLC (filed as Exhibit 10.26 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2002 and incorporated herein by reference).
10.3		First Amendment, dated June 17, 2003, to Lease Agreement dated April 23, 2002, with Phase 3 Science Center LLC, Ahwatukee Hills Investors LLC and J. Alexander’s LLC (filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2003 and incorporated herein by reference).
10.4		Second Amendment, dated February 4, 2004, to Lease Agreement dated April 23, 2002, with Phase 3 Science Center LLC, Ahwatukee Hills Investors LLC and J. Alexander’s LLC (filed as Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2003 and incorporated herein by reference).
10.5		Lease Agreement for facilities at 80 Davids Drive, Hauppauge, NY, effective as of July 1, 2005 (filed as Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2005 and incorporated herein by reference).
10.6		Lease Agreement for facilities at 3830 Monte Villa Parkway, Bothell, WA, with Ditty Properties Limited Partnership, effective as of March 1, 2006 (filed as Exhibit 10.1 to Amendment No. 1 to the Company’s Current Report on Form 8-K/A dated March 1, 2006 and filed on July 26, 2006 and incorporated herein by reference).(1)

Exhibit
No.		Description
10.7		First Amendment, dated July 17, 2006, to Lease Agreement dated March 1, 2006 with Ditty Properties Limited Partnership for facilities at 3830 Monte Villa Parkway, Bothell, WA (filed as Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 and incorporated herein by reference).
10.8		Amended and Restated Employment Agreement, dated May 2, 2002, with Steven C. Quay, M.D., Ph.D. (filed as Exhibit 10.27 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2002 and incorporated herein by reference).
10.9		Employment Agreement dated June 3, 2005 by and between Nastech Pharmaceutical Company Inc. and Steven C. Quay, M.D., Ph.D. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated June 3, 2005 and incorporated herein by reference).
10.10		Amended and Restated Employment Agreement dated December 16, 2005 by and between Nastech Pharmaceutical Company Inc. and Steven C. Quay, M.D., Ph.D. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated December 16, 2005 and incorporated herein by reference).
10.11		Employment Agreement effective as of January 1, 2006 by and between Nastech Pharmaceutical Company Inc. and Philip C. Ranker (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated January 1, 2006 and incorporated herein by reference).
10.12		Employment Agreement effective as of August 17, 2006 by and between Nastech Pharmaceutical Company Inc. and Gordon C. Brandt, M.D. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated August 17, 2006 and incorporated herein by reference).
10.13		Employment Agreement effective as of September 15, 2006 by and between Nastech Pharmaceutical Company Inc. and Timothy M. Duffy (field as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated September 15, 2006 and incorporated herein by reference).
10.14		Termination and Mutual Release Agreement, dated September 30, 2002, with Schwarz Pharma, Inc. (Filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K dated September 30, 2002 and incorporated herein by reference).
10.15		Divestiture Agreement, dated January 24, 2003, with Pharmacia & Upjohn Company (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated January 24, 2003 and incorporated herein by reference).
10.16		Nastech Pharmaceutical Company Inc. 1990 Stock Option Plan (filed as Exhibit 4.2 to the Company’s Registration Statement on Form S-8, File No. 333-28785, and incorporated herein by reference).
10.17		Amended and Restated Nastech Pharmaceutical Company Inc. 2000 Nonqualified Stock Option Plan (filed as Exhibit 4.4 to the Company’s Registration Statement on Form S-8, File No. 333-49514, and incorporated herein by reference).
10.18		Amendment No. 1 to the Amended and Restated Nastech Pharmaceutical Company Inc. 2000 Nonqualified Stock Option Plan. (filed as Exhibit 10.18 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 and incorporated herein by reference).
10.19		Amendment No. 2 to the Amended and Restated Nastech Pharmaceutical Company Inc. 2000 Nonqualified Stock Option Plan. (2).
10.20		Nastech Pharmaceutical Company Inc. 2002 Stock Option Plan (filed as Exhibit 10.28 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2002 and incorporated herein by reference).

Exhibit
No.		Description
10.21		Amendment No. 1 to the Nastech Pharmaceutical Company Inc. 2002 Stock Option Plan. (filed as Exhibit 10.20 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 and incorporated herein by reference).
10.22		Nastech Pharmaceutical Company Inc. 2004 Stock Incentive Plan (filed as Exhibit 99 to the Company’s Registration Statement on Form S-8, File No. 333-118206, and incorporated herein by reference).
10.23		Amendment No. 1 to Nastech Pharmaceutical Company Inc. 2004 Stock Incentive Plan (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K dated July 20, 2005 and incorporated herein by reference).
10.24		Amendment No. 2 to Nastech Pharmaceutical Company Inc. 2004 Stock Incentive Plan (filed as Exhibit 10.18 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2005 and incorporated herein by reference).
10.25		Amendment No. 3 to Nastech Pharmaceutical Company Inc. 2004 Stock Incentive Plan. (filed as Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 and incorporated herein by reference).
10.26		Amendment No. 4 to Nastech Pharmaceutical Company Inc. 2004 Stock Incentive Plan. (filed as Exhibit 10.5 to the Company’s Registration Statement on Form S-8, File No. 333-135724, and incorporated herein by reference).
10.27		Amendment No. 5 to Nastech Pharmaceutical Company Inc. 2004 Stock Incentive Plan. (2).
10.28		Restricted Stock Grant Agreement effective July 20, 2005 by and between Nastech Pharmaceutical Company Inc. and Dr. Steven C. Quay, M.D., Ph.D. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated July 20, 2005 and incorporated herein by reference).
10.29		Incentive Stock Option Grant Agreement effective July 20, 2005 by and between Nastech Pharmaceutical Company Inc. and Dr. Steven C. Quay, M.D., Ph.D. (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated July 20, 2005 and incorporated herein by reference).
10.30		Non-Qualified Stock Option Grant Agreement effective July 20, 2005 by and between Nastech Pharmaceutical Company Inc. and Dr. Steven C. Quay, M.D., Ph.D. (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K dated July 20, 2005 and incorporated herein by reference).
10.31		Amendments to Certain Grant Agreements effective as of July 20, 2005 by and between Nastech Pharmaceutical Company Inc. and Steven C. Quay, M.D., Ph.D. (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated December 16, 2005 and incorporated herein by reference).
10.32		Stock Option Agreement dated as of August 25, 2004 between Nastech Pharmaceutical Company Inc. and Mr. Philip C. Ranker (filed as Exhibit 10.34 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2005 and incorporated herein by reference).
10.33		Restricted Stock Grant Agreement effective August 25, 2004 by and between Nastech Pharmaceutical Company Inc. and Mr. Philip C. Ranker (filed as Exhibit 10.35 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2005 and incorporated herein by reference).
10.34		Restricted Stock Grant Agreement effective July 1, 2005 by and between Nastech Pharmaceutical Company Inc. and Mr. Philip C. Ranker (filed as Exhibit 10.36 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2005 and incorporated herein by reference).

Exhibit
No.		Description
10.35		Restricted Stock Grant Agreement effective September 7, 2005 by and between Nastech Pharmaceutical Company Inc. and Mr. Philip C. Ranker. (filed as Exhibit 10.38 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2005 and incorporated herein by reference).
10.36		Restricted Stock Grant Agreement effective as of January 1, 2006 by and between Nastech Pharmaceutical Company Inc. and Philip C. Ranker (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated January 1, 2006 and incorporated herein by reference).
10.37		Incentive Stock Option Grant Agreement dated as of January 1, 2006 by and between Nastech Pharmaceutical Company Inc. and Philip C. Ranker (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K dated January 1, 2006 and incorporated herein by reference).
10.38		Non-Qualified Stock Option Grant Agreement dated as of January 1, 2006 by and between Nastech Pharmaceutical Company Inc. and Philip C. Ranker (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K dated January 1, 2006 and incorporated herein by reference).
10.39		Restricted Stock Grant Agreement effective January 21, 2005 by and between Nastech Pharmaceutical Company Inc. and Mr. Gordon Brandt, M.D. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated January 21, 2005 and incorporated herein by reference).
10.40		Stock Option Agreement dated as of January 21, 2005 between Nastech Pharmaceutical Company Inc. and Mr. Gordon Brandt, M.D.(filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated January 21, 2005 and incorporated herein by reference).
10.41		Restricted Stock Grant Agreement effective December 16, 2005 by and between Nastech Pharmaceutical Company Inc. and Dr. Gordon C. Brandt (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K dated December 16, 2005 and incorporated herein by reference).
10.42		Stock Option Agreement dated as of December 16, 2005 between Nastech Pharmaceutical Company Inc. and Dr. Gordon C. Brandt (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K dated December 16, 2005 and incorporated herein by reference).
10.43		Restricted Stock Grant Agreement effective January 21, 2005 by and between Nastech Pharmaceutical Company Inc. and Mr. Paul H. Johnson, Ph.D. (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K dated January 21, 2005 and incorporated herein by reference).
10.44		Restricted Stock Grant Agreement effective October 5, 2005 by and between Nastech Pharmaceutical Company Inc. and Dr. Paul H. Johnson, Ph.D (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated October 5, 2005 and incorporated herein by reference).
10.45		Stock Option Agreement dated as of January 21, 2005 between Nastech Pharmaceutical Company Inc. and Mr. Paul H. Johnson, Ph.D. (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K dated January 21, 2005 and incorporated herein by reference).
10.46		Stock Option Agreement dated as of October 5, 2005 between Nastech Pharmaceutical Company Inc. and Dr. Paul H. Johnson, Ph.D. (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated October 5, 2005 and incorporated herein by reference).
10.47		Restricted Stock Grant Agreement effective May 25, 2005 by and between Nastech Pharmaceutical Company Inc. and Mr. David E. Wormuth (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K dated May 25, 2005 and incorporated herein by reference).

Exhibit
No.		Description
10.48		Stock Option Agreement dated as of May 25, 2005 between Nastech Pharmaceutical Company Inc. and Mr. David E. Wormuth (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K dated May 25, 2005 and incorporated herein by reference).
10.49		Restricted Stock Grant Agreement effective as of January 30, 2006 by and between Nastech Pharmaceutical Company Inc. and Timothy M. Duffy (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated January 30, 2006 and incorporated herein by reference).
10.50		Incentive Stock Option Grant Agreement dated as of January 30, 2006 by and between Nastech Pharmaceutical Company Inc. and Timothy M. Duffy (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated January 30, 2006 and incorporated herein by reference).
10.51		Non-Qualified Stock Option Grant Agreement dated as of January 30, 2006 by and between Nastech Pharmaceutical Company Inc. and Timothy M. Duffy (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K dated January 30, 2006 and incorporated herein by reference).
10.52		Restricted Stock Grant Agreement effective August 11, 2004 by and between Nastech Pharmaceutical Company Inc. and Mr. Bruce R. York. (filed as Exhibit 10.33 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2005 and incorporated herein by reference).
10.53		Restricted Stock Grant Agreement effective July 1, 2005 by and between Nastech Pharmaceutical Company Inc. and Mr. Bruce R. York (filed as Exhibit 10.37 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2005 and incorporated herein by reference).
10.54		Restricted Stock Grant Agreement effective September 7, 2005 by and between Nastech Pharmaceutical Company Inc. and Mr. Bruce R. York (filed as Exhibit 10.39 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2005 and incorporated herein by reference).
10.55		Restricted Stock Grant Agreement effective July 14, 2006 by and between Nastech Pharmaceutical Company Inc. and Mr. Bruce R. York (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated July 14, 2006 and incorporated herein by reference).
10.56		Amendments to Certain Grant Agreements by and between Nastech Pharmaceutical Company Inc. and Gordon C. Brandt, M.D. (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated August 17, 2006 and incorporated herein by reference).
10.57		Amendments to Certain Grant Agreements by and between Nastech Pharmaceutical Company Inc. and Timothy M. Duffy (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated September 15, 2006 and incorporated herein by reference).
10.58		Asset Purchase Agreement dated June 16, 2003, by and between the Company and Questcor Pharmaceuticals, Inc. (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K dated June 17, 2003 and incorporated herein by reference).
10.59		Form of Purchase Agreement (filed as Exhibit 99.2 to the Company’s Current Report on Form 8-K dated September 4, 2003 and incorporated herein by reference).
10.60		Form of Warrant (filed as Exhibit 99.3 to the Company’s Current Report on Form 8-K dated September 4, 2003, and incorporated herein by reference).
10.61		Revolving Line of Credit Agreement with Wells Fargo Bank, dated December 19, 2003 (filed as Exhibit 10.20 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2003 and incorporated herein by reference).

Exhibit
No.		Description
10.62		Addendum to Promissory Note with Wells Fargo Bank, dated January 20, 2004 (filed as Exhibit 10.21 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2003 and incorporated herein by reference).
10.63		Security Agreement Securities Account with Wells Fargo Bank, dated December 19, 2003 (filed as Exhibit 10.22 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2003 and incorporated herein by reference).
10.64		Addendum to Security Agreement: Securities Account with Wells Fargo Bank, dated December 19, 2003 (filed as Exhibit 10.23 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2003 and incorporated herein by reference).
10.65		Revolving Line of Credit Agreement with Wells Fargo Bank, dated October 20, 2004 (filed as Exhibit 10.29 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2004 and incorporated herein by reference).
10.66		Exclusive Development, Commercialization and License Agreement by and between Merck & Co., Inc. and the Company effective as of September 24, 2004 (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated September 24, 2004 and incorporated herein by reference).(1)
10.67		Supply Agreement by and between the Company and Merck & Co., Inc. effective as of September 24, 2004 (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated September 24, 2004 and incorporated herein by reference).(1)
10.68		License and Supply Agreement by and between Par Pharmaceutical, Inc. and Nastech Pharmaceutical Company Inc. effective as of October 22, 2004 (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated October 22, 2004 and incorporated herein by reference).(1)
10.69		Agreement dated as of September 23, 2005 by and between Nastech Pharmaceutical Company Inc. and QOL Medical, LLC. (filed as Exhibit 10.1 to Amendment No. 1 to the Company’s Current Report on Form 8-K/A dated October 17, 2005 and filed on July 26, 2006 and incorporated herein by reference).(1)
10.70		Product Development and License Agreement by and between Nastech Pharmaceutical Company Inc. and Procter & Gamble Pharmaceuticals, Inc. dated January 27, 2006 (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated January 27, 2006 and incorporated herein by reference).(1)
10.71		Supply Agreement by and between Nastech Pharmaceutical Company Inc. and Procter & Gamble Pharmaceuticals, Inc. dated June 2, 2006 (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated June 2, 2006 and incorporated herein by reference).(1)
10.72		Development and License Agreement by and between Nastech Pharmaceutical Company Inc. and Amylin Pharmaceuticals, Inc. dated June 23, 2006.(1) (filed as exhibit 10.66 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 and incorporated herein by reference).
10.73		Employment Agreement effective as of November 1, 2006 by and between Nastech Pharmaceutical Company Inc. and Paul H. Johnson, Ph.D. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated November 1, 2006 and incorporated herein by reference).
31.1		Certification of the Company’s Chairman of the Board, President and Chief Executive Officer pursuant to Rules 13a–14 and 15d-14 under the Securities Exchange Act of 1934, as amended.(2)
31.2		Certification of the Company’s Chief Financial Officer pursuant to Rules 13a–14 and 15d-14 under the Securities Exchange Act of 1934, as amended.(2)
32.1		Certification of the Company’s Chairman of the Board, President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(2)

Exhibit
No.		Description
32.2		Certification of the Company’s Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(2)